Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 1of 95Clinical Study Protocol
Drug Substance Dapagliflozin
Study Code D169CC00001
Version 4.[ADDRESS_536702] of Dapagliflozin on Reducing CV Death or 
Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection 
Fraction (HFpEF)
DELIVER -Dapagliflozin Evaluation to Improve the LIVEs of P atients 
with PReserved Ejection Fraction Heart Failure
Sponsor: [COMPANY_008] AB, 151 85 Södertälje, Sweden
Regulatory Agency Identifying Number(s):
Eudra CT number: 2018 -000802 -46
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 5of 956. 8. Study  
Assessments and 
ProceduresIt was clarified that during Visit 1, the investigator assesses pat ient’s 
eligibilit y criteria and reviews concomitant medications, and relevant 
medicat ions will be recorded.
COVID -19 testing was added to Safety  events assessment during Visits: 
3,4,5,6,7 and onwards, as well as Premature Treatment Discont inuat ion 
Visit and Study  Closure Visi t.
It was clarified that starting from Visit 6, vital signs (BP, pulse), and 
weight assessment as well as blood samples collectio n for creatinine (for 
calculat ion of eGFR) will be repeated every  [ADDRESS_536703] ion of 
adverse eventsThe process of Adjudicati on of potential  DKA events by [CONTACT_424610] (section [IP_ADDRESS].2.)
Requi rements for capturing of Maj or hy poglycaemic events were added as 
section [IP_ADDRESS].
10.9.[ADDRESS_536704] the dual primary  hypothesis, changed multiple 
testing procedure and increased event target.
11.9.3 Popul ations 
for analysisA subset of the full analysis set consisting of patients with baseline LVEF 
of <60% (or LVEF <60% subpopulation) will be analysed separately as part 
of the confi rmatory  stati stical test ing procedure added to full analysis set.
12.9.[ADDRESS_536705] to analysis of 
recurrent HF events and CV death for the LVEF < [ADDRESS_536706] 
procedures. The Clinical Study  Protocol  is publicly  registered and the resul ts are di sclosed and/or 
published according to the [COMPANY_008] Global Policy  on Bioethics and in compliance with 
prevailing laws and regulat ions.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 6of 95TABLE OF CONTENTS
TITLE PAGE ............................................................................................................................................ [ADDRESS_536707] ivities (SoA) .............................................................................................. 12
1.2 Synopsis ................................................................................................................................ 15
1.3 Schema .................................................................................................................................. 19
2. INTRODUCTION .............................................................................................................. 20
2.1 Study  rationale ..................................................................................................................... 20
2.2 Background........................................................................................................................... 21
2.3 Benefit/risk assessment ...................................................................................................... 21
2.3.1 Potenti al risks to patients ................................................................................................... 22
[IP_ADDRESS] Protecti on against ri sks...................................................................................................... [ADDRESS_536708] ions (not applicable) ............................................................................. 33
5.4 Screen failures ...................................................................................................................... 33
5.5 Procedures for handling of rando mized not eligible patients ..................................... 34
6. STUDY TREATMENTS .................................................................................................. 35
6.1 Treatments administered .................................................................................................... 35
6.2 Preparati on/handling/storage/accountabilit y................................................................. 35
6.3 Measures to minimise bias: rando misat ion and blinding ............................................ 36
6.3.1 Stratificat ion and cappi[INVESTIGATOR_007] .................................................................................................. 37
[IP_ADDRESS] Stratificat ion......................................................................................................................... 37
[IP_ADDRESS] Cappi[INVESTIGATOR_007] ................................................................................................................................. 37
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 7of 956.[ADDRESS_536709] of care ..................................................................... 38
6.5.4 Anti-diabetes treatm ent...................................................................................................... 38
[IP_ADDRESS] Background........................................................................................................................... 38
[IP_ADDRESS] Treatment of patients with established diagnosis of ty pe 2 diabetes ........................ 38
6.5.5 Other concomitant treatment ............................................................................................ 39
6.6 Dose m odificat ion (not applicable) ................................................................................. [ADDRESS_536710] WITHDRAWAL ...39
7.1 Discontinuati on of  study  treatm ent................................................................................. 39
7.1.1 Temporary  discont inuat ion............................................................................................... 39
[IP_ADDRESS] Unexpected acute declines in eGFR ................................................................................ 40
[IP_ADDRESS] Volume deplet ion/hypotensio n......................................................................................... 40
[IP_ADDRESS] Patients at ri sk of  volume depletion ................................................................................ [ADDRESS_536711] to follow -up................................................................................................................. 41
7.3 Withdrawal fro m the study ................................................................................................ 41
8. STUDY ASSESSMENTS AND PROCEDURES ....................................................... 42
8.1 Enrolment Period ................................................................................................................. 42
8.1.1 Visit 1, Enrolment (Day  -21 to Day  -1).......................................................................... 42
8.2 Treatment period ................................................................................................................. 43
8.2.1 Visit 2, Randomisati on (Day  1)........................................................................................ 43
8.2.2 Visit 3 (Day  30; ±7 days): ................................................................................................. 44
8.2.3 Visit 4 (Day  120 ±7 days): ................................................................................................ 44
8.2.4 Visit 5 (Day  240 ±7 days) ................................................................................................. 45
8.2.5 Visit 6 (Day  360 ±7 days) ................................................................................................. 45
8.2.6 Visit 7 and onwards (Day  480 and every  120 days ±14 days) ................................... 46
8.2.7 Prem ature Treatment Discont inuat ion Visit .................................................................. 46
8.2.8 Study  Closure Visi t............................................................................................................. 47
8.2.9 Unscheduled visits .............................................................................................................. 47
8.3 Efficacy assessments .......................................................................................................... 48
8.3.1 Efficacy event capture ........................................................................................................ 48
8.3.2 Efficacy event adjudicat ion............................................................................................... 48
8.3.3 Clinical Outcome Assessments (COA) .......................................................................... 48
[IP_ADDRESS] KCCQ .................................................................................................................................... 48
[IP_ADDRESS] Patient Gl obal Impressi on of Severi ty (PGIS) .............................................................. 49
[IP_ADDRESS] EuroQoL five -dimensio nal five -level quest ionnaire (EQ -5D- 5L)............................ 49
[IP_ADDRESS] Administrati on of  electroni c PROs ................................................................................. 50
8.4 Safety assessment ................................................................................................................ 50
8.4.1 Physical examinat ions........................................................................................................ 51
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 8of 958.4.2 Vital Signs ............................................................................................................................ 51
8.4.3 Electrocardiogram ............................................................................................................... 51
8.4.4 Safety laboratory  assessments .......................................................................................... 51
8.4.5 Other safet y assessments ................................................................................................... 51
8.4.6 Other clinical assessments ................................................................................................. 51
[IP_ADDRESS] Body  weight and height ..................................................................................................... [ADDRESS_536712] ion of adverse events ............................................................................................. 52
8.5.1 Method of detecting AEs and SAEs ................................................................................ 52
[IP_ADDRESS] Adverse events (AEs) leading to amputation and potential risk factor AEs for
amputati ons affect ing lower limbs (“preceding events”) ........................................... 52
[IP_ADDRESS] Capture of DKA events ...................................................................................................... 52
8.5.1. 2.1DKA definit ion................................................................................................... 53
8.5.1. 2.2Diabetic Ketoacidosis Adjudicat ion Committee T2D .......................................... 53
[IP_ADDRESS] Capture of cardiac ischaemic events and stroke .................................................. 53
[IP_ADDRESS] Capture of Major hypoglycaemic events ............................................................. 53
[IP_ADDRESS] Capture of addit ional laboratory  values .......................................................................... [ADDRESS_536713] ion........................................................................................... 54
8.5.5 Causalit y collection ............................................................................................................. 55
8.5.6 Adverse events based on signs and symptoms .............................................................. 55
8.5.7 Adverse events based on examinat ions and tests ......................................................... 55
8.5.8 Disease -under study  (DUS) (not applicable) ................................................................. 56
8.5.9 Disease progressi on (not applicable) .............................................................................. 56
8.6 Safety reporti ng and medical management .................................................................... 56
8.6.1 Reporting of serious adverse events ................................................................................ 56
[IP_ADDRESS] Reporting of SAEs considered to be potential endpoints ........................................... 56
8.6.2 Pregnancy.............................................................................................................................. 57
[IP_ADDRESS] Maternal exposure ............................................................................................................... 57
8.6.3 Overdose ............................................................................................................................... 57
8.7 Pharmacokinet ics (not applicable) ................................................................................... 58
8.8 Pharmacodynamics (not applicable) ............................................................................... 58
8.9 Optional exploratory  genet ics........................................................................................... 58
8.10 Biomarkers (not applicable) .............................................................................................. 58
8.11 Heal th Economics (not applicable) .................................................................................. 58
9. STATISTICAL CONSIDERATIONS ........................................................................... 58
9.1 Statistical hypotheses ......................................................................................................... 58
9.2 Sample size determinat ion................................................................................................. 58
9.3 Popul ations for analyses .................................................................................................... 60
9.4 Statistical analyses .............................................................................................................. 60
9.4.1 Efficacy analyses ................................................................................................................. 60
[IP_ADDRESS] Analysis of the primary  variable ...................................................................................... 60
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 9of [IP_ADDRESS] Analysis of the secondary  variables ................................................................................ 61
[IP_ADDRESS] Subgroup analysis ............................................................................................................... 61
[IP_ADDRESS] Sensit ivity analysis .............................................................................................................. 62
9.4.2 Safety analyses ..................................................................................................................... 62
9.4.3 Methods for mult iplicit y control ...................................................................................... 62
9.5 Interim analyses ................................................................................................................... 62
9.5.1 Data m onitoring committee (DMC) ................................................................................ [ADDRESS_536714] OF APPENDICES
Appendix A Regulatory , ethi cal and study  oversight considerations ............................... 69
Appendix B Adverse event definit ions and addit ional safet y inform ation..................... 72
Appendix C Cardi ovascular rel ated events ............................................................................ 76
Appendix D Genet ics.................................................................................................................. 79
Appendix E Handling of Human Bio logical  Samples ......................................................... 82
Appendix F Actions required in cases of increases in liver biochemistry and
evaluat ion of Hy’s Law (not applicable) ........................................................ 84
Appendix G Medical device incidents: definit ion and procedures for recording,
evaluat ing, fo llow-up, and reporti ng (not applicable) .................................. 84
Appendix H Abbreviat ions........................................................................................................ 85
Appendix I [LOCATION_001] Heart Associat ion (NYHA) Funct ional Cl assificat ion............. 86
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 10of 95Appendix J The KC Cardio myopathy Quest ionnaire ......................................................... 86
Appendix K EQ-5D- 5L Questionnaire ................................................................................... 91
Appendix L Patient Gl obal Impressi on of Severi ty for Heart Failure Symptoms ......... 95
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 11of 951. PROTOCOL SUMMARY
1.1 Schedule of Activities (SoA)
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 12of 95Table 1 Study of Assessments
Visit 1
Enrolment2
Randomisation3 4 5 6 7 –
onwardsPremature
Treatment
Discontinuation
VisitStudy
Closure
VisitFor details
see Section:
Day/Month Day -21 to
Day -1Day 1 Day 30
(±7)Day 120
(±7)Day 240
(±7)Day 360
(±7)Day 480 -
onwards
(every 120
days ±14
days)≤ 6 weeks
after
PACD
Infor med consent X65.1,A 3
Inclusion/exclusion
criteria X X 5.1, 5.2
Demographics X 5.1
Medical history X X 5.1
Concomitant
medication X X X X X X X X X 6.5
Cardiac and HF
related procedures X X X X X X X [IP_ADDRESS]
Physical exam X X X 8.4.1
Systolic and
diastolic BP X X X X3X3X X 5.2,8.4.2
Pulse X X X X3X3X X 5.2,8.4.2
Weight X X3X3X X [IP_ADDRESS]
Height X [IP_ADDRESS]
NYHA classification X X X X X X X5.1,
Appendix I
12-lead ECG X 8.4.3
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 13of 95Visit 1
Enrolment2
Randomisation3 4 5 6 7 –
onwardsPremature
Treatment
Discontinuation
VisitStudy
Closure
VisitFor details
see Section:
Day/Month Day -21 to
Day -1Day 1 Day 30
(±7)Day 120
(±7)Day 240
(±7)Day 360
(±7)Day 480 -
onwards
(every 120
days ±14
days)≤ 6 weeks
after
PACD
C-lab NT -proBNP X 5.1
C-lab eGFR
(creatinine) X X X X3X35.2,8.4.4
C-lab HbA1c X [IP_ADDRESS]
Sample for genetic
research, if
applicable5X Appendix D
KCCQ X4X4X4X4X4X48.3.3.1
PGIS X4X4X4X4X4X48.3.3.2
EQ-5D-5L X4X4 X4 X4 [IP_ADDRESS]
Local pregnancy test
(fema le patients with
childbearing
potential only) X 5.[ADDRESS_536715] (IP) X X X X X [ADDRESS_536716] unused IP;
check IP compliance X X X X X X 6
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 14of 95Visit 1
Enrolment2
Randomisation3 4 5 6 7 –
onwardsPremature
Treatment
Discontinuation
VisitStudy
Closure
VisitFor details
see Section:
Day/Month Day -21 to
Day -1Day 1 Day 30
(±7)Day 120
(±7)Day 240
(±7)Day 360
(±7)Day 480 -
onwards
(every 120
days ±14
days)≤ 6 weeks
after
PACD
Efficacy events
(death and
worsening heart
failure) 1X1X X X X X X X 8.3
Safety events2,7X X X X X X X X X 8.4
AEs Adverse events; DAEs Adverse events leading to discontinuation of investigational product; PACD Primary Analysis Censoring Date; SAEs 
Serious adverse events; C -lab Central laboratory
1Efficacy events are considered as endpoints from time of randomisation and throughout the study. Prior to randomisation, these events are considered as SAEs.
2SAEs will be recorded from the time of informed consent. DAEs and Amputations, adverse events (AEs) leading to amputation and potential risk factor AEs 
for amputations affecting lower limbs will be re corded from Visit 2 onwards.3Assessments to be repeated ever y 12 mo nths (Visit 6, Visit 9, Visit 12).
4Will be administered using a site -based electronic device. It is preferred that PRO questionnaires are completed prior to any other study procedures an d 
before discussion of disease progression to avoid biasing the patient’s responses to the questions5Blood sample for future genetic research is optional. The genetic sampling is subject to separate consent by [CONTACT_102].
6The Patient signs the ICF. Patie nts who agree to the optional sampling of blood for genetic research will provide their consent.
7Including recording of COVID -19 testing results from Visit 2 onwards. 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 16of 95Table 2 Objectives and Endpoints
Primary objective: Endpoint/variable:
To deter mine whether dapagliflozin is superior 
to placebo, when added to standard of care, in 
reducing the composite of CV death and HF 
events (hospi[INVESTIGATOR_424556]) 
in patients with HF and preser ved systolic 
function in
full study population 
subpopulation with LVEF <60%Time to the first occurrence of any of the 
components of this composite: 
1.CV death
2.Hospi[INVESTIGATOR_15528]
3.Urgent HF visit (e.g., emergency 
department or outpatients visit)
Secondary objective: Endpoint/variable:
To deter mine whether dapagliflozin is superior 
to placebo in reducing the total number of HF 
events (hospi[INVESTIGATOR_424556]) 
and CV death in 
full study population
subpopulation with LVEF <60%Total number of HF events (first and 
recurre nt) and CV death
To deter mine whether dapagliflozin is superior 
to placebo in improving Patient Reported 
Outcomes measured by [CONTACT_424611] (TSS) of the KCCQ at 8 months
To deter mine whether dapagliflozin is superior 
to placebo in reducing CV deathTime to the occurrence of CV death 
To deter mine whether dapagliflozin is superior 
to placebo in reducing all -cause mortalityTime to the occurrence of death from any 
cause
Safety objective:
To evaluate the safety and tolerability of 
dapagliflozin compared to placebo in patients 
with HFpEFSerious adverse events (SAEs), adverse 
events leading to treatment discontinuation 
(DAEs), amputations, adverse events (AEs) 
leading to amputation and potential risk 
factor AEs for amputations affecting lower  
limbs
Exploratory Objective:
To deter mine whether dapagliflozin is superior 
to placebo in reducing all -cause hospi[INVESTIGATOR_424557] –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 17of 95To deter mine whether dapagliflozin is superior 
to placebo in reducing the proportion of patients 
with worsened NYHA classProportion of patients with worsened NYHA 
class from baseline to 8 months
To describe health status assessed by [CONTACT_424612]-dimensional five-level questionnaire (EQ-
5D-5L) to support health economic analysis and 
health technology assessmentResults will be reported separately in a health 
economic report
To determine whether dapagliflozin compared 
with placebo will have an effect on systolic BPChange in systolic BP from baseline
To determine whether dapagliflozin compared 
with placebo will have an effect on body 
weightChange in body weight from baseline
To deter mine whether dapagliflozin compared 
with placebo will have an effect on eGFR.Change in eGFR from baseline
To explore whether dapagliflozin compared to 
placebo improves KCCQ summary scores, 
subscores of TSS (Symptom frequency and 
symptom burden) and domainsChange in Clinical summary score, TSS 
subscores, Overall summary score, QoL score
To collect and store blood samples for future 
exploratory genetic researchNot applicable. Results will be reported separately
BP Blood pressure; CV Cardiovascular; EQ -5D-5L EuroQol five -dimensio nal five -level questionnaire
HF Heart failure; HFrEF Heart failure with reduced ejection fraction; KCCQ Kansas City Cardiomyopathy 
Questionnaire NYHA [LOCATION_001] Heart Association
Overall design:
This is an internat ional, mult icentre, parallel -group, event -driven, randomised, double -blind study 
in patients with HFpEF, evaluat ing the effect of dapagliflozin [ADDRESS_536717] of care therapy , including treatments to control 
co-morbidities, in reducing the composite of CV death and heart failure events (hospi[INVESTIGATOR_424558] s). Adult pat ients aged ≥40 y ears wit h HFpEF (LVEF >40% and evidence 
of structural  heart disease) and [LOCATION_001] Heart Associat ion (NYHA) class II -IV who are eligible 
according to the inclusio n/exclusio n criteria will be randomised in a 1:1 ratio to receive either 
dapagliflozin 10 mg or placebo. Both out -patients and in -patients hospi[INVESTIGATOR_424559]-therapy  for 24 hours can be rando mised. It is estimated that 
approxim ately  [ZIP_CODE] patients at approximately 400-500 sites in 20-25 countries will need to be 
enrolled to reach approximately 6100 rando mised patients.
Study Period:
Estimated date of first patient enro lled: Q3 [ADDRESS_536718] patient completed: Q4 2021
Number of randomised Subjects: approximately 6100 patients
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 18of 95Treatments and treatment duration:
Patients will be rando mised in a 1:1 ratio to receive either dapagliflozin 10 mg or placebo once 
daily . The original ant icipated average treatment durati on was 24 months (range 15 to 33  months). 
With updated sample size and increased target number of events, the maximum treatm ent durati on 
is expected to be approximately 39 m onths.
Data Monitoring Committee:
An independent Data Moni toring Committee (DMC) will review accumulat ing trial data by 
[CONTACT_424613] y and efficacy, ensure the validit y and integri ty of 
the trial, and make benefit -risk assessment.
Statistical methods
This study is event-driven with a target of [ADDRESS_536719] of care, in reducing the composite of CV death and HF events (hospi[INVESTIGATOR_424560]). Two hypotheses will be tested simultaneously (i.e, dual primary analy ses) for this primary 
objective: (1) in the full population and in(2)an LVEF <60% subpopulation, with alpha allocated to 
each test. The final alpha split will be defined in the SAP prior to the interim analysis. It is anticipated 
that at least 70% of the events (i.e. approximately 780 events) will be available for the LVEF <60% 
subpopulation. To illustrate, assuming a true hazard ratio (HR) of 0.80 between dapagliflozin and 
placebo, a two -sided alpha of 1.5% would yield a power of 90% for the full population and a two -sided 
alpha of 2.4% would yield a power of 80% for the L VEF <60% subpopulation. 
Based on above assumption and ongoing blinded monitoring of events accrual, approximately 6100 
patients are estimated to provide the required number of primary events in the full population during 
an anticipated recruitment period up to 29 months and followed until the pre-specified number of 
primary events has occurred. Randomisation will be stratified by [CONTACT_424614] 2 
Diabetes (T2D).
All patients who have been randomised to study treatment will be included in theFull Analysis Set 
(FAS) irrespective of their protocol adherence and continued participation in the study. The primar y 
variable is the time to first event included in the primary composite endpoint. The primary analysis will 
be based on the intention to t reat (ITT) principle using the FAS, including events occurring on or prior 
to the primary analysis censoring date (PACD), confirmed by [CONTACT_73485].
In the analysis of the primary  composite endpo int, treatments (dapagliflozin versus placebo) will 
be compared using a Cox proporti onal hazards model with a factor f or treatm ent group, stratified 
by [CONTACT_24975] 2 diabetes (T2D) status at randomisat ion. The p-value, hazard ratio and 95% confidence 
interval  will be reported.
Interim analysis is planned to be performed including approximately  67% of target number of 
adjudicated primary endpoints.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 20of 952. INTRODUCTION
2.1 Study rationale
The prevalence of chronic HF continues to increase globally. An estimated 38 millio n people are 
affected worldwide (Braunwald 2015 ), with over 1 millio n hospi [INVESTIGATOR_424561] ( Ambrosy et al  2014 ). The annual  global economic burden in 2012 was 
estimated to be $108 billio n, (Cook et al 2014); this will increase dram atically as the popul ation 
ages.
Heart failure is a complex syndrom ecaused by [CONTACT_424615]/or functional abnorm alities. It is 
characterised by [CONTACT_103433], fatigue, and pulmo nary congest ion and/or peripheral oedema due to 
fluid retenti on. Pati ents wi th signs and symptoms of HF are categorised, based on measurement o f 
left-ventri cular eject ion fraction (LVEF), as having HF with reduced LVEF (HFrEF) or HF wi th 
preserved LVEF (HFpEF).
Approximately  half of  all heart failure pat ients have HFpEF ( Oktay  et al  2013 ). Risk of  death for 
HFpEF pat ients is high, wi th annualised mortalit y rate up to 15% in communi ty settings ( Lam et 
al 2011). In controlled clinical trials, patients with HFpEF tend to be older and have a higher
prevalence o f hypertensio n as compared to patients with HFrEF, although major clinical outcomes 
are similarly dominated by [CONTACT_424616] [INVESTIGATOR_72913], the yearly event rates appear to be 
lower than in HFrEF (Solomon et al 2005). However, patients with HFpEF have a particularly 
significant unmet medical need given that outcome studies hitherto performed have not resulted in 
any approved pharm acotherapy  specifically for this condi tion. Conversely , outc ome studi es have 
provi ded evidence for treatm ents for HFrEF that hence can improve symptoms and 
haemodynamics as well as reduce hospi[INVESTIGATOR_424562] y. These treatments 
include diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, 
angiotensin II recept or blocker neprilysin inhibitors, mineralocortico id receptor antagonists, and 
beta-blockers ( Iwaz et al  2016 ).
Recent data from cardio vascular (CV) outcome trials of SGLT2 inhibitors (empagliflozin and 
canagliflozin) indicate that treatment with SGLT2 inhibitors can reduce the risk of CV death and 
hospi [INVESTIGATOR_424563] T2D overall , and in pat ients with T2D and concomitant 
HF (Zinman et al 2015 ; Fitchett et al 2016 ; Neal et al  2017 ; Rådho lm et al 2018).
Results from real-world observat ional studies are broadly  consistent with the randomised clinical 
trials in supporting the benefits of SGLT2 inhibitors in reducing risk of HF hospi[INVESTIGATOR_424564]. The CVD -REAL study , consisting of more than 300000 patients with T2D, both with and 
without established CV disease, across 6 countries found that patients treated with SGLT2 
inhibitors compared to patients treated with other glucose lowering drugs was associ ated with a 
relative risk reduction in hospi[INVESTIGATOR_424565] (39%), all -cause death (51%), and the composite 
of hospi [INVESTIGATOR_424566] (46%) ( Kosiborod et al 2 017a ).
Limitat ions associated with the rando mised clinical  trials as well as the observat ional studi es are 
that only patients with T2D were studied, and that the proporti on of patients with HFrEF and 
HFpEF, respect ively, is unknown.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 21of 95This study  will simul taneously test the two hy potheses that dapagliflozin is superior to placebo in 
reducing the composite of CV death and HF events (hospi [INVESTIGATOR_424567]) in 
patients with HF and preserved systolic funct ion (LVEF >40%), with or wi thout T2D, in (1) the 
full popul ation and in (2)an LVEF <60% subpopulat ion.
2.[ADDRESS_536720] ive and orally  active inhibitor of human renal  SGLT2. A 
detailed description of the chemistry, pharmacology, efficacy, and safety  of dapagliflozin is 
provi ded in the Investi gator’s Brochure. Supporting the hypothesis that dapaglifl ozin may reduce 
CV Death and HF events in HF pati ents, i rrespective of di abetes status, are observat ions from the 
overall dapagliflo zin clinical devel opmen t programme. Dapagliflozin lowers HbA1c with a low 
risk of inducing hypoglycaemia. In addit ion, dapagliflo zin treatment has also been shown to reduce 
weight and systolic blood pressure, and to have favourable effect on increased blood uric acid, 
albuminuri a, and arterial elasticity, conditions which are associ ated with increased CV and renal 
risk (Shigiyama et al 2017 ). Dapagliflozin is believed be nephroprotective through non -glycaemic 
mechanisms ( Wanner et al 2016 ).
The ident ified blood pressure lowering effects, may reduce the primary outcom e in a study 
popul ation with high prevalence of hypertensi on, similarly, the observed effects on body  weight, 
may be beneficia l to the large part of the study popula tion with obesit y. The findings from EMPA -
REG, with a similar SGLT2 inhibitor compound, suggests that kidney funct ion is preserved, or 
improved in this diabet ic study  population. Furtherm ore, HFpEF patients are characterized by 
[CONTACT_424617] a change in cardiac metabo lism favouring glucose as substrate, both of which 
has been hypothesised to be posit ively impacted by [CONTACT_23265]2 inhibitor treatm ent. Moreover, arterial 
stiffness, and abnorm al ventriculo -arteri al coupling, are commo n in p atients with HFpEF, and ma y 
be modified by  [CONTACT_23265]2 inhibitor treatments.
The clinical studies in healt hy subjects at high mult iple doses also show that, due to the mechanism 
of action, dapagliflozin does not induce hypoglycemia in nondiabet ic subjects; however, 
pharmacodynamic effects on glucose, sodium, and urinary  volume are observed. Therefore, the 
changes in these diabetes -independent mechanisms and intrarenal physi ology are expected to be 
similar regardless of underlying disease.
This study  is an internat ional, multicentre, parallel -group, event -driven, rando mised, doubl e-blind, 
placebo -controlled study  in HFpEF patients, evaluating the effect of dapagliflozin [ADDRESS_536721] of care therapy , including treatm ents to 
control  co-morbidities, in reducing the co mposite of CV death and heart failure events 
(hospi [INVESTIGATOR_424568] s).
2.3 Benefit/risk assessment
Dapagliflozin has global marketing approval  in approximately  [ADDRESS_536722] igator’s Brochure. The following is a summary of 
benefit -risk consi derati ons rel evant to the HFpEF target populat ion.
2.3.1 Potential risks to patients
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 22of 95Dapagliflozin reduces blood volume and blood pressure from its diuretic effect, which could be a 
concern in patients with HFpEF, but also be important mechanisms of a potential treatment effect. 
However, in the dapagliflozin type 2 diabetes mellitus (T2D) program, the rate of events related to 
volume depletion and impaired renal function have been similar between dapagliflozin and placebo. 
Loop -diuretics are widely used in the target patient population and are also allowed in this study. A 
pooled analy sis of patients with T2D and HF in the dapagliflozin development program, showed no 
increase of volume depletion even ts but increase in renal events, mainly creatinine increases, in patients 
treated with dapagliflozin (n=171) compared with placebo treated patients (n=149). About half of the 
patients were on loop diuretics ( Kosiborod et al 2017b ).
An increase in amputations, mostly affect ing toes, was observed in a clinical trial ( Neal et al 2017 ) 
with another SGLT2 inhibi tor. There is no indicat ion fro m the clinical  devel opment program  that 
dapagliflozin is associ ated with an increased risk of amputation (see Secti on [IP_ADDRESS] for the 
detection and capture of amputation events).
Dapagliflozin has not been shown to induce hypoglycaemia in non-diabetes patients. In clinical 
pharmaco logy studi es, healthy subjects have been treated with single oral doses up to [ADDRESS_536723] -market ing reports of ketoacidosis, including diabet ic ketoacidosis, in patients 
with T2D taking dapaglifl ozin and other SGLT2 inhibi tors, al though a causal  relationship has not 
been established.
Patients treated with dapagliflozin who present with signs and symptom s consistent with 
ketoacidosis, including nausea, vo miting, abdo minal pa in, malaise, and shortness of breath, should 
be assessed for ketoacidosis, even if blood glucose levels are below 14 mmo l/L (250 mg/dL). If 
ketoacidosis is suspected interruption of dapagliflozin treatm ent shoul d be considered and the 
patient shoul d be pro mptly evaluated.
Predi sposing factors to ketoacidosis include a low beta-cell funct ion reserve resul ting from 
pancreat ic disorders (e.g., T1D, history  of pancreatit is, or pancreatic surgery ), insulin dose 
reducti on, reduced caloric intake, or increased insulin requi rements due to infections, illness or 
surgery  and alcoho l abuse. Dapagliflo zin should be used with caution in patients in these 
circumstances. Dapagliflozin is current ly no t indicated for the treatm ent of patients with T1D; these 
patients are excluded fro m this study .
[IP_ADDRESS] Protection against risks
This study  has been designed with appropriate measures in place to monitor and minimise any 
potenti al risks to parti cipating pat ients. Data regarding amputations and adverse events 
potenti ally placing the patient at risk for a lower limb amputation will be collected (see Section 
[IP_ADDRESS] ). To ensure the safet y of all patients parti cipating in [COMPANY_008] sponsored studies, 
reviews o f all safet y information fro m all ongoing clinical dapagliflozin studies are conducted as 
they become available. In addit ion, an independent Data Monitoring Co mmittee (DMC) will be 
responsible for safeguarding the interests of the patients by [CONTACT_424618] y data throughout the 
study (see Section 9.5.1).
2.3.2 Potential benefits to patients
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 23of 95All patients in the study are expected to be optimally treated according to regional standard of care 
therapy , including treatm ents to control co-morbidit ies, and dapagliflo zin or placebo will be 
administered on top of this treatment.
All patients participating in clinical trials irrespective of whether treated with active treatm ent or 
not, generally receive closer medical attenti on than those in ordinary  clinical pract ice which may 
be to their advantage.
2.3.[ADDRESS_536724] ive treatments.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 24of 953. OBJECTIVES AND ENDPOINTS
Table 3 Study objectives
Primary objective: Endpoint/variable:
To deter mine whether dapagliflozin is superior 
to placebo, when added to standard of care, in 
reducing thecomposite of CV death and HF 
events (hospi[INVESTIGATOR_424556]) 
in patients with HF and preser ved systolic 
function in
full study population
subpopulation with LVEF <60% Time to the first occurrence of any of the 
components of this compos ite: 
4.CV death
5.Hospi[INVESTIGATOR_15528]
6.Urgent HF visit (e.g., emergency 
department or outpatients visit)
Secondary objective: Endpoint/variable:
To deter mine whether dapagliflozin is superior 
to placebo in reducing the total number of HF 
events (hospi[INVESTIGATOR_424556]) 
and CV death in 
full study population
subpopulation with LVEF <60%Total number of HF events (first and 
recurrent) and CV death
To deter mine whether dapagliflozin is superior 
to placebo in improving Patient Reported 
Outcomes measured by [CONTACT_424611] (TSS) of the KCCQ at 8 months
To deter mine whether dapagliflozin issuperior 
to placebo in reducing CV deathTime to the occurrence of CV death 
To deter mine whether dapagliflozin is superior 
to placebo in reducing all -cause mortalityTime to the occurrence of death from any 
cause
Safety objective:
To evaluate the safety and tolerability of 
dapagliflozin compared to placebo in patients 
with HFpEFSerious adverse events (SAEs), adverse 
events leading to treatment discontinuation 
(DAEs), amputations, adverse events (AEs) 
leading to amputation and potential risk 
factor AEs for amputations affecting lower  
limbs
Exploratory Objective:
To deter mine whether dapagliflozin is superior 
to placebo in reducing all -cause hospi[INVESTIGATOR_424557] –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 25of 95To deter mine whether dapagliflozin is superior 
to placebo in reducing the proportion of patients 
with worsened NYHA classProportion of patients with worsened NYHA 
class from baseline to 8 months
To describe health status assessed by [CONTACT_424612]-dimensional five-level questionnaire (EQ-
5D-5L) to support health economic analysis and 
health technology assessmentResults will be reported separately in a health 
economic report
To determine whether dapaglifloz in compared 
with placebo will have an effect on systolic BPChange in systolic BP from baseline
To determine whether dapagliflozin compared 
with placebo will have an effect on body 
weightChange in body weight from baseline
To deter mine whether dapagliflozin compared 
with placebo will have an effect on eGFR.Change in eGFR from baseline
To explore whether dapagliflozin compared to 
placebo improves KCCQ summary scores, 
subscores of TSS (Symptom frequency and 
symptom burden) and domainsChange in Clinical summary score, TSS 
subscores, Overall summary score, QoL score
To collect and store blood samples for future 
exploratory genetic researchNot applicable. Results will be reported separately
BP Blood pressure; CV Cardiovascular; EQ -5D-5L EuroQo l five -dimensio nal five -level questionnaire
HF Heart failure; HFrEF Heart failure with reduced ejection fraction; KCCQ Kansas City Cardiomyopathy 
Questionnaire NYHA [LOCATION_001] Heart Association
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 26of 954. STUDY DESIGN
4.[ADDRESS_536725] of care therapy, including treatments to control 
co-morbidities, in reducing the composite of CV death or heart failure events.
For an overview of the study  design see Figure 1 , Secti on 1.3 . For details on treatm ents given 
during the study , see Secti on 6.1.
For details on what is included in the efficacy and safet y endpo ints, see Section 3Objectives and 
Endpoints.
Adult pat ients with HFpEF (defined for the purposes of this study as LVEF >40% and evidence o f 
structural  heart disease) aged ≥40 years and with NYHA class II-IV who meet the inclusio n 
criteria, and none of the exclusi on criteria, will be randomised in a 1:[ADDRESS_536726] acebo. Randomised treatment shoul d be started as soon as possible and 
within 24 hours after randomisation. It is estimated that approximately [ZIP_CODE] patients at 
approximately 400-500 sites in 20-25 countri es will be enrolled to reach approxima tely 6100 
rando mised pat ients (see Section 9.2).
Study  closure procedures will be initiated when the predetermined number of primary endpo ints 
are predicted to have occurred (n=1117), i.e. the Primary Analysis Censoring Date (PACD). 
Patients shoul d be scheduled for a Study Closure Visit (SCV) wit hin [ADDRESS_536727] of the study  treatm ent is 
detected during the DMC review, or due to DMC recommendat ions fo llowing pre-specified interim 
analyses ( see Sect ion 9.5).
Data on baseline characterist ics, endpo ints and AEs will be co llected through a validated electronic 
data capture (EDC) sy stem  with electroni c case report forms (eCRFs).
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 27of 954.2 Scientific rationale for study design
This is a rando mised, mult i-centre, double -blind, parallel -group study . Rando misat ion and double -
blinding will minimise potential bias. The target populat ion includes adult (aged ≥ 40 years) male 
and female pat ients with HFpEF, which is defined in this study  as individuals with an established 
diagnosis of heart failure and a LVEF >40% and structural  heart disease who meet natriuretic 
pepti de threshol ds. The requi rement of demo nstrated structural heart disease (i.e. left ventricular
hypertrophy  or left atrial enlargement1)and elevated natriuret ic pepti des aims to support the 
diagnosis of heart failure, since other commo n co-morbidities may cause overl appi[INVESTIGATOR_395399] s. 
Most randomised patients will be out -patients. However, to address a specific need in a period wit h 
high risk for events, a proportion o f patients will be enrolled and rando mised during hospi[INVESTIGATOR_424569] 30 days of discharge from  hospi[INVESTIGATOR_424570] (subacute 
subgroup).
The study  population will include patients both with and without T2D, as the beneficial 
haemodynamic effects of dapagliflozin appear to be independent of the glycaemic effect, and can 
therefore be expected in both groups. Enrolment in the study  may be capp ed based on the 
proporti on of patients with/without T2D, in certain LVEF categori es, in each NYHA class, 
with/without atrial fibrillat ion, randomised during or early after HF hospi [INVESTIGATOR_72913] (subacute 
subgroup), and geographic regio n.
The control  group will receive placebo; there are no approved pharmaco logical treatm ents for 
HFpEF that could be utilised as a comparator. All patients will be treated according to local 
guidelines on standard of care treatm ent for patients with HFpEF, focusing on treatm ent of HF 
symptoms (e.g. diuret ics) and comorbidi ties (including treatm ent for high blood pressure, 
ischaemic heart disease, atrial fibrillat ion).
The study  popul ation will include pati ents wi th eGFR ≥ 25 ml /min/1.73m2. Pati ents wi th reduced 
renal funct ion have a clinical pi[INVESTIGATOR_424571]-glomerul ar pressure, hypertensio n, 
proteinuria and fluid/sodium overl oad and SGLT2 inhibit ion can improve all these abnorm alities 
through metabolic -independent mechanisms. Thus, patients with heart failure and reduced renal 
funct ion could be expected to benefit from treatment with dapagliflo zin.
The primary  efficacy endpo ints of the study are adjudicated CV death and HF events 
(hospi [INVESTIGATOR_424567]). The rationale for select ing CV death over all-cause 
death is the expectati on that HF treatm ent will decrease CV death and not all potenti al causes of 
death ( Zannad et al 2014 ). Heart failure events include both HF hospi[INVESTIGATOR_424572] (according to CDISC definit ions; Hicks et al 2014 ; Hicks et al 2018 ). These are the
same endpo int definit ions currently empl oyed in the Sponsor’s HFrEF outcom e study  (Dapa -HF; 
Study  D1699C00001).
1Left Atrial Enlargement defined by [CONTACT_2669] 1 of the following: LA width (diameter) ≥3.8 cm or LA length 
≥5.0 cm o r LA area ≥20 cm2or LA volume ≥55 mL or LA volume index ≥29 mL/m
2Left Ventricular Hypertrophy defined by [CONTACT_424619] ≥1.1 c m
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 28of 95The rationale for including outpatient HF events, in addit ion to hospi[INVESTIGATOR_76114], is that it is the 
occurrence of worsening of the patient’s condi tion necessitating treatm ent, and not the place of 
treatm ent, that is important. As stated in EMA Guidance 2016, ‘…patient are often managed for 
epi[INVESTIGATOR_424573] (eg, emergency 
departm ents, observat ion units, other outpati ent settings). The capture of events of worsening HF 
without hospi [INVESTIGATOR_424574].’ Including only hospi [INVESTIGATOR_424575] a m odest but si gnificant proporti on of  epi[INVESTIGATOR_424576] 
(Skali et al 2014 , Okumura et al 2016, Greene et al 2018 ).
While CV death and HF hospi[INVESTIGATOR_424577] i mportant to patients and healt h-care system s, 
the impact of HF on patients’ symptoms and physical/social funct ioning is also important. In order 
to evaluate the treatment effects on these aspects of the impact of HF, we will use the Kansas Cit y 
Cardi omyopathy Questi onnai re (KCCQ), a disease -specific patient reported outcom es (PRO) 
measure developed for patients with chronic HF. The KCCQ has shown to be a valid, reliable and 
responsive measure for patients with HF (Greene et al 2018 , Spertus et al 2005 ).
There has been a gradual accumulat ion of data that HF patients with mildly abnorm al (or “mid -
range”) eject ion fraction (LVEF 40-50%), although traditionally classified as HFpEF, may 
potenti ally benefit from therapi[INVESTIGATOR_424578] ( Nauta et 
al 2017). During the course of the DELIVER trial, the PARAGON -HF trial was completed, 
rando mizing patients with HFpEF to sacubitril/valsartan or valsart an alone. While the study failed 
to meet its primary  objective (Solomon et al 2019), there appeared to be a different ial treatm ent 
effect by [CONTACT_424620] t largely seen in patients with LVEF 45-60% (Solomon et al 2020 ). 
This new data suggests that HFpEF with a high-norm al LVEF may const itute different clinical 
entities than heart failure wi th low-norm al or mildly  reduced LVEF ( Lam et al  2020 ). To account 
for this emerging information in DELIVER, it was decided to formally investi gate the treatm ent 
effect in both the subset of patients with LVEF<60% and in the full study  populati on.
4.3 Justification fordose
The 10 mg dose of dapaglifl ozin has a well-characteri sed efficacy and safety profile in the T2D 
clinical devel opment program  and is the recommended dose in the majorit y of countri es 
worldwide.
From  a  pharm acokinetic perspective, the current ly approved dapagliflozin dose of 10 mg once 
daily is appropriate for use in patients with HFpEF. Slightly higher systemic exposure to 
dapagliflozin is expected in HFpEF patients when symptom atic, based on the dual renal and hepat ic 
metabo lism of dapagliflozin and the lower perfusio n of these organs in this patient group. However, 
the increase in systemic exposure of 10 mg dapagliflo zin is not anticipated to warrant dose 
adjustm ent in HF patients. Moreover, the anticipated slight ly higher systemic exposure to 
dapagliflozin is likely to be beneficial in HF patients, by [CONTACT_424621] n and consequent ly lower renal  glucose and sodi um fil tered l oads in these pat ients. Doses 
lower than 10 mg are therefore unlikely  to provi de as m uch benefit to pati ents wi th HF as the 10 -
mg dose. Lastly, no changes in dose of conco mitant medicat ions in the HFpEF popul ation are 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 29of 95needed due to a lack of clinically meaningful drug -drug interactions for dapagliflozin wit h current 
medicat ions used for treatm ent of patients with HFpEF, including standard of care medications 
used to control co-morbidities in this pat ient group.
In the dapagliflozin clinical program , there are no dose-related SAEs that preclude the use of [ADDRESS_536728]-hoc analysis of data from 320 patients with a 
docum ented history  of HF and concomitant T2D in placebo -controlled clinical trials, dapagliflozin 
10 m g was f ound to be well tolerated in this population ( Kosiborod et al 2017b ).
There are mechanist ic reasons for choosing the 10- mg dose as well. One hypothesis of underlying 
pathophysio logy in HFpEF is abnormal pressure coupling between the left ventricle and aorta, and 
drugs that reduce aortic st iffness may have beneficial effects in pat ients with HFpEF ( Borlaug and 
Paulus 2011). Studies examining the highest approved dose for empagliflozin have reported
improvements in aortic elasticity (Chilton et al 2015 ,Cherney et al 2014); similar studi es are 
ongoing with dapagliflo zin. In a completed placebo -controlled study, treatment with dapagliflo zin 
10 mg resul ted in improvements in param eters associated with arteri al remodelling in addition to 
lowering blood pressure in patients with T2D (Ott et al 2017 ). This prior work suggests that 
select ing the 10-mg dose of dapagliflozin is reasonable from a mechanist ic perspective to 
demonstrate a clinical effect.
4.[ADDRESS_536729] expected visit/contact [CONTACT_96747] .
The study  may be terminated at individual study  sites if the study  procedures are not being 
perform ed according to GCP, or if no patients are recruited. Patients from terminated sites will 
have the opportuni ty to be transferr ed to another site to continue the study . [COMPANY_008] may also 
terminate the ent ire study  prem aturely  if concerns for safet y arise wi thin this study  or in any other 
study  with dapagliflozin, or due to recommendat ion by [CONTACT_1363]. Regardless of the reason for
termination, all data required by [CONTACT_424622]-up will be 
collected. In terminating the study, the Sponsor will ensure that adequate considerat ion is given to 
the protection of the patients’ interests.
See Appendi x A 6for guidelines for the dissemination of study  resul ts.
5. STUDY POPULATION
Prospective approval o f protocol  deviati ons to recrui tment and enro lment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
In this protocol, ‘enrolled’ pat ients are defined as those who sign the informed consent form (ICF) 
and received E-Code. The ICF process is described in Appendix A 3. ‘Rando mised’ patients are 
defined as those who undergo randomisation and receive a rando misat ioncode.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 30of 95Patients are eligible to be randomised in the study only if all o f the fo llowing inclusio n criteria and 
none of  the exclusi on criteria apply. Enrolled pati ents who for any  reason are not randomised are 
considered screen failures (see Sect ion 5.4).
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 31of 955.1 Inclusion criteria
Subjects are eligible to be rando mised in the study only if all o f the following incl usion criteria 
and none of the exclusio n criteria apply:
1.Provisio n of signed informed consent prior to any study specific pro cedures.
2.Male or female pat ients age ≥40 y ears.
3.Docum ented di agnosis of symptom atic heart failure (NYHA class II -IV) at enrolm ent, 
and a medical history  of typi[INVESTIGATOR_103404]/ signs2of heart failure ≥[ADDRESS_536730] ion Fraction (LVEF) >40% and evidence of structural heart 
disease (i .e. left ventricular hy pertrophy  or left atrial  enlargement3) documented by [CONTACT_424623], and/or cardi ac MR within the last [ADDRESS_536731] 12 weeks fo llowing the procedure/event is required.
5.NT-pro BNP ≥300 pg/ml at Visit 1 for patients without ongoing atrial fibrillat ion/flutter. 
If ongo ing atrial fibrillat ion/flutter at Visit 1, NT -pro BNP must be ≥600 pg/mL.
6.Patients may be ambulatory , or hospi[INVESTIGATOR_057]; patients must be off intravenous heart 
failure therapy  (including diureti cs) for at least 12 hours prior to enrolment and 24 hours 
prior to randomisat ion.
2Typi[INVESTIGATOR_424579]: breathlessness, orthopnoea, paroxysmal nocturnal dyspnoea, 
reduced exercise tolerance, fatigue, tiredness, increased time to recover after exercise, ankle swelling;
Signs associated with Heart Failure:
More specific: elevated jugular venous pressure, hepatojugular reflex, third heart sound (gallop rhythm), laterally 
displaced api[INVESTIGATOR_424580]: weight gain (>2 kg/week), weight loss (in advanced HF), tissue wasting (cachexia), cardiac murmur, 
peripheral oedema (ankle, sacral, scrotal), pulmonary crepi[INVESTIGATOR_814], reduced air entry and dullness to percussion at lung 
bases (pleural effusion), tachy cardia, irregular pulse, tachy pnoea, cheyne stokes respi[INVESTIGATOR_1516], hepatomegaly, ascites, 
cold extremities, oliguria, narrow pulse pressure
3Left Atrial Enlargement defined by [CONTACT_2669] 1 of the following: LA width (diameter) ≥3.8 cm or LA length ≥5.0 cm 
or LA area ≥20 cm2or LA volume ≥55 mL or LA volume index ≥29 mL/m2. Left Ventricular Hypertrophy defined by 
[CONTACT_424619] ≥1.1 cm
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 32of 955.2 Exclusion criteria
1.Receiving therapy  with an SGLT2 inhibitor wi thin 4 weeks pri or to randomisat ion or 
previous intolerance to an SGLT2 inhibitor .
2.Type 1 di abetes m ellitus (T1D) .
3.eGFR <25 mL/min/1.73 m2(CKD -EPI f ormula) at Visi t 1.
4.Systolic bl ood pressure (BP) <95 mmHg on 2 consecutive measurements at 5 -minute 
intervals, at Vi sit 1 or at Vi sit 2.
5.Systolic BP≥160 mmHg if not on treatm ent with ≥3 blood pressure lowering medications 
or ≥[ADDRESS_536732] ive of treatm ents, on 2 consecut ive measurements at 5-minute 
intervals, at Vi sit 1 or at Vi sit 2.
6.MI, unstable angina, coronary revascularizat ion (percutaneous coronary intervent ion (PCI) 
or coronary artery  by[CONTACT_15806] (CABG)), ablation of atrial flutter/fibrillat ion, valve 
repai r/repl acement within [ADDRESS_536733] their qualifying echocardi ography  and/or cardiac MRI examinat ion at least 12 
weeks after the event.
7.Planned corona ry revascularizat ion, ablat ion of atrial flutter/fibrillat ion and valve 
repai r/repl acement.
8.Stroke or transient ischemic attack (TIA) within [ADDRESS_536734] igator 
could account for the patient's HF symptoms and signs (e.g. anaemia, hypothy roidism) .
10.Body  mass index >50 kg/m2.
11.Primary pulmo nary hypertensio n, chronic pulmo nary embo lism, severe pulmo nary disease 
including COPD (i.e., requi ring home oxygen, chroni c nebulizer therapy  or chronic oral 
steroi d therapy , or hospi [INVESTIGATOR_424581] 12 m onths prior to enrolment) .
12.Previous cardiac transplantation, or complex congenital heart disease. Planne d cardiac 
resynchronisation therapy .
13.HF due to any  of the f ollowing: known infil trative cardi omyopathy (e.g. amyl oid, sarcoi d, 
lympho ma, endo myocardi al fibrosi s), active myocardi tis, constrictive pericardi tis, cardiac 
tamponade, known genet ic hypertrophi ccardi omyopathy  or obstructive hypertrophic 
cardi omyopathy , arrhy thmogenic right ventricular cardi omyopathy /dysplasia (ARVC/D), 
or uncorrected primary  valvular disease .
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 33of 9514.A life expectancy o f less than 2 y ears due to any  non-cardi ovascular condit ion, based on 
investigator's clinical judgement.
15.Inabilit y of the patient, in the opi[INVESTIGATOR_3078] n of the investigator, to understand and/or comply wit h 
study  medicat ions, procedures and/or follow-up OR any condi tions that, in the opi[INVESTIGATOR_424582], may render the patient unable to com plete the study .
16.Active malignancy requiring treatment (with the except ion of basal cell or squamous cell 
carcino mas of the skin).
17.Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, 
oesophageal va rices, coagul opathy ).
18.Women of child -bearing potential (i.e. those who are not chemically or surgically sterilised 
or post-menopausal) not willing to use a medically accepted method of contraception 
considered reliable in the judgment of the invest igator OR who have a posi tive pregnancy 
test at randomisat ion OR who are breast -feeding .
19.Involvement in the planning and/or conduct of the study (applies to both [COMPANY_008] 
personnel and/or personnel at the study  site).
20.Previous rando misation in the present study .
21.Parti cipation in another clinical study  with an IP or device during the last month prior to 
enrolment .
5.3 Lifestyle restrictions (not applicable)
5.4 Screen failures
Enrolled pat ients who are found not eligible (i.e. not m eeting all the inclusio n criteria or f ulfilling 
any of the exclusio n criteria) must not be randomised or init iated on treatment.
Screen failures are defined as pati ents who si gned the informed consent form to parti cipate in the 
study  but are not subsequent ly rando mised. A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure patients to meet the Conso lidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queri es from regul atory  
authori ties. Minimal information includes demography , eligibilit y criteria (reason for screen 
failure), and any serious adverse event (SAE).
Screen failures may be re-enrolled one time during the study  if the Investi gator considers that the 
patient may be eligible for participat ion in this study  at another time point. Re-enrolled patients 
shoul d be assigned the same enrolment code as for the init ial enrolment. All enro lment assessments 
and procedures, including signing the informed consent form, should be performed again.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 34of 955.[ADDRESS_536735] be discontinued in all cases where continued treatment is deemed to pose a safety 
risk to the patient. Regardless of whether study treatment is discontinued or not, the patient should 
continue his/her participation in the study for follow -up of endpoints and other protocol -defined study 
procedures until the end of the study . Consistent with the intention -to-treat principle, all randomised 
patients are included in the efficacy analy sis according to randomised treatment assignment. The 
[COMPANY_008] Study Physician must ensure that the protocol deviation and the rationale for the decision 
to discontinue or continue study treatment are appropriately documented.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 35of 956. STUDY TREATMENTS
Study  treatm ent is defined as any invest igational product(s) (including marketed product 
comparator and placebo) or medical device(s) intended to be administered to a study participant 
according to the study  protocol . Study treatm ent in this study  refers to dapaglifl ozin or m atchin g 
placebo.
6.[ADDRESS_536736] will 
be provided in bottles. Each 
bottle will be labelled in 
accordance with Good 
Manufacturing Practice 
Annex 13 and per country 
regulatory requirements
Provider [COMPANY_008] [COMPANY_008]
The tablets contain lactose, in quantit ies not likely to cause discomfort in lactose -intolerant 
individuals.
6.2 Preparation/handling/storage/accountability
The invest igator or designee must confirm appropri ate temperature condi tions have been 
maintained during transi t for all study  treatm ent received and any discrepancies are reported and 
resolved before use of the study  treatm ent.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 36of 95All invest igational product (IP) should be kept in a secure place under appropriate storage 
condi tions. The label on the IP bottle specifies the appropriate storage.
Only patients rando mised in the study may receive IP and only authorised site staff may supply or 
administer IP. The administration of all inves tigati onal products should be recorded in the 
appropriate sections of the eCRF.
The Investigator is responsible for IP accountability, reconciliat ion, and record maintenance (i.e.
recei pt, reconciliat ion, and final disposit ion records).
The invest igator will retain the returned IP until the AZ representative or delegate collects it, along 
with any IP not dispensed. The AZ representative or delegate is responsible for confirming the 
investigator or delegate has recorded the quant ities of returned and unus ed tablets at a patient level 
before IP is destroyed. The AZ representative or del egate will advise on the appropri ate method 
for destructi on of  unused IP.
6.3 Measures to minimise bias: randomisation and blinding
All patients will be centrally  assigned to randomised IP using an interactive voice/web response 
system  (IxRS). Randomisat ion to IP will be performed in balanced blocks to ensure approximate 
balance between the treatment groups (1:1). The randomisat ion codes will be computer generated 
and loaded into the IxRS database. Before the study is initiated, the tel ephone number and call -in 
directions for the IxRS and/or the l og-in informat ion and di rections for the IxRS will be provi ded 
to each site.
If a randomised patient withdraws from the study , then his/her enrolment/rando misat ion code 
cannot be reused. Withdrawn randomised patients will be included in the intent ion to t reat analysis.
The IxRS will provide the Investigator with the kit ident ificat ion number to be allocated to the 
patient at each dispensing visit. At all visits where IP is dispensed, site personnel will do a kit 
verification in IxRS before providing the IP bottle to the patient. Routines for this will be described 
in the IxRS user manual that will be provided to each centre.
The blinding of treatment is ensured by [CONTACT_2329] a double -blind technique. Individual treatment codes, 
indicat ing the rando mised treatm ent for each patient, will be available to the investigator(s) or 
pharmacists from the IxRS. Instructions for code breaking/unbl inding will be described in the IxRS 
user m anual  that will  be provi ded to each site.
The randomisat ion code should not be broken except in medical emergencies when the appropriate 
management of the pat ient requi res knowl edge o f the treatment rando misat ion. The Invest igator is 
to document and report the action to [COMPANY_008], without revealing the treatm ent given to the 
patient to the [COMPANY_008] staff.
[COMPANY_008] retains the ri ght to break the code for SAEs that are unexpected and are suspected to 
be cau sally related to an investigational product and that potentially require expedited reporting to 
regul atory  authori ties. Rando misation codes will not be broken for the planned analyses of data 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 37of 95until all decisio ns on the evaluabilit y of the data from  each in dividual pat ient have been made and 
docum ented.
6.3.1 Stratification and cappi[INVESTIGATOR_424583]-popul ations.
[IP_ADDRESS] Stratification
Randomisat ion will be stratified in IxRS based on patients with and without T2D at the time of 
rando misat ion in order to ensure approximate bal ance between treatment groups within each sub -
popul ation. Stratificat ion on T2D at the time of randomisat ion is based on:
Established diagnosis of T2D
OR
HbA1c ≥6.5% (48 mmo l/mol) shown at central laboratory  test at enrolment (Visit 1)
[IP_ADDRESS] Cappi[INVESTIGATOR_424584]  a typi[INVESTIGATOR_424585] -section of  patients wi th HFpEF and to i nclude representative 
proporti ons of diabet ic and non-diabet ic patients. The number of rando mised patients with and 
without T2D will be monitored in order to ensure a minimum of 30% in each sub-popul ation. 
Randomisat ion may be capped (i.e., no more patients can be randomised in a specific sub-
popul ation) if the pre -deter mined limit is reached.
Randomisat ion of patients based on geographi c region will be monitored to ensure global 
representation. LVEF value, NYHA class, subacute subgroup (i.e. randomised in-hospi [INVESTIGATOR_424586] 30 days from discharge) and atrial fibrillat ion status at Visit [ADDRESS_536737] Storage Manager is responsible for managing IP fro m receipt by  [CONTACT_424624]. The Investigator(s) is responsible for 
ensuring that the patient has returned all unused IP.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 38of 956.[ADDRESS_536738] ing 
comorbidi ties (including treatm ent of hypertension, ischemic heart disease, atrial fibrillat ion, 
diabetes, hyperlipi[INVESTIGATOR_17939]). Background medicat ions shoul d be part of clinical pract ice and will 
not be provi ded by [CONTACT_1034].
6.5.1 Prohibited medication
Concomitant treatm ent (i.e., treatm ent in combinatio n with IP) with open label SGLT2 inhibitors 
e.g., dapagliflo zin, em paglifl ozin, canaglifl ozin, ertuglifl ozin, tof oglifl ozin and luseogliflozin an d
fixdose combinat ions containing these drugs shoul d not be used. Also in situations when the 
patient is not on IP, treatm ent with open label SGLT2 inhibitors during the study  could interfere 
with the interpretati on of study results. If treatment with an SGLT2 inhibitor alone or in 
combinat ion is deemed essent ial, IP m ust be di scont inued bef ore that treatm ent is started.
6.5.2 Recording of concomitant treatment
Recording of relevant concomitant medicat ions in t he eCRF will be made according to the schedule 
of activit ies (Table 1 ).These include medicat ions for cardiovascular condit ions as well as diabetes 
mellitus.
6.5.[ADDRESS_536739] of care therapi [INVESTIGATOR_424587], including diuret ics when needed to control symptom s and vo lume overload and 
adequate treatment of co -morbidities such as hypertension and ischaemic heart disease.
6.5.4 Anti- diabetes treatment
[IP_ADDRESS] Background
More than 40% of patients wit h established HF are estimated to have T2D ( Kristensen et al 2016 ). 
Therefore, it is expected that a large proportion of patients will have an established T2D diagnosis 
when included in this study and that some pat ients will develop T2D during the course of the study. 
Treatment of di abetes shoul d follow established gui delines, such as according to glycaemic goals 
as recommended by [CONTACT_11026] (ADA) and European Association for the 
Study  of Diabetes (EASD) in their joint Position Statem ent (Inzucchi et al 2012 , Inzucchi et al 
2015 ).
[IP_ADDRESS] Treatment of patients with established diagnosis of type 2 diabetes
Diabetes medicat ions at baseline and during the study  will be recorded in the eCRF. Pati ents wi th 
T2D at randomisat ion will cont inue their T2D treatment. SGLT2 -inhibitors should be avoided (see 
Secti on 6.5.1 ). Patients treated with insulin or insulin secretagogues have a higher risk of 
experiencing hypoglycaemic events compared wit h those treated with other antidiabet ic agents. If 
needed, T2D treatm ents may be adjusted at the discretion of the Invest igator or diabetes healt h care 
provider.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 39of 956.5.5 Other concomitant treatment
Medicat ions other than described above, which is considered necessary for the patient’s safet y 
and wellbeing, may be given at the discret ion of the Invest igator.
6.6 Dose modification (not applicable)
6.7 Treatment after the end of the study
The patients will stop taking IP at the study closure visit (SCV). Remaining IP will be co llected at 
that time. Post-study treatm ent will not be provided by [CONTACT_1034]. Patients shoul d receive 
standard of care therapy after the SCV, at the discretion of the Invest igator.
7. DISCONTINUATION OF TREATMENT AND SUBJECT 
WITHDRAWAL
7.1 Discontinuation of study treatment
Discontinuati on fro m study treatment is NOT the same thing as a withdrawal fro m the study. If the 
patient temporarily or permanent ly discont inues IP, the patient should remain in the study and it is 
important that the scheduled study  visits and data collection continue according to the study 
protocol  until study  closure.
Patients m ay be di scontinued from IP in the following si tuations:
Contraindicat ion to further dosing with IP, in the opi[INVESTIGATOR_3078] n of the Invest igator, such as 
Adverse event or other safet y reasons.
Severe non -compliance wi th the study  protocol .
Diabetic ketoacidosis (DKA). Consider temporarily interrupting IP if DKA is suspected. 
If DKA is confirmed, IP should be discont inued permanent ly.
Positive pregnancy  test (di scont inue IP and notify Sponsor representative).
Patient deci sion. The pati ent is at any t ime free to discontinue treatment, without 
prejudice to further treatment.
See the Table [ADDRESS_536740] igator, the 
patient’s condi tion is stable.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 40of [IP_ADDRESS] Unexpected acute declines in eGFR
If an unexpected, acute decline in kidney funct ion is observed, the patient should be evaluated and 
temporary  interrupti on of IP shoul d be considered. Volume deplet ion, hypotensio n, inter-current
medical probl ems and conco mitant drugs may cause increases in blood creatinine. Urinary  tract 
infect ion and urinary obstruction should be considered (the latter especially in men). Several drugs 
may cause a decline in kidney function, especially non -stero idal ant i-inflammatory  drugs (NSAID) 
and certain ant ibiotics such as trimethoprim. If any drug is suspected of causing or contributing to 
worsening kidney  function, thei r use shoul d be re -considered.
[IP_ADDRESS] Volume depletion/hypotension
Patients with clinically relevant symptoms/signs of suspected volume depleti on and/or 
hypotension, shoul d in addition to considering temporary  interrupti on of IP have their regul ar 
medicat ion reviewed, and considerat ion given to reducing the dose of, or stoppi [INVESTIGATOR_424588],as assessed on an individual basis, including diuretics and drugs that lower blood 
pressure. The need for convent ional diuretics (or the dose of diuret ic used) should be re -evaluated 
in light of the patient’s symptoms and signs.
[IP_ADDRESS] Patients at risk of volume depletion
Temporary  interrupti on of IP may be considered in patients thought to be at risk of volume 
depletion/hypotension, such as patients with an acute medical illness potenti ally causing volume 
depletion because of inadequat e fluid intake or fluid/blood loss (e.g. gastroenteritis, gastrointest inal 
haemorrhage), or those undergoing major surgery .
7.1.[ADDRESS_536741] the site before or at the time IP is stopped. A 
patient that deci des to di scont inue IP will always be asked about the reason(s) and the presence of 
any AEs. Generally, AEs, SAEs, and potential  endpo int events shoul d not lead to IP 
discontinuat ion, unless there is a clear cl inical rat ionale to do so.
The date of last intake of IP shoul d be docum ented in the eCRF. All IP shoul d be returned by  [CONTACT_424625] r next on -site study  visit or unscheduled visit. Patients permanently discont inuing IP 
shoul d be given l ocally avail able standard of care therapy, at the discretion of the Invest igator.
Discontinuati on of IP, for any reason, does not impact on the patient´s partici pation in the study . 
The pati ent shoul d continue attending subsequent study  visits and data collection sho uld continue 
according to the study  protocol . If the patient does not agree to continue in-person study  visits, a 
modified fo llow-up m ust be arranged to ensure the collect ion of endpo ints and safet y information. 
This could be a telephone contact [CONTACT_10970], a contact [CONTACT_4490] a relative or treating physician, 
or information from medical records. The approach taken shoul d be recorded in the medical 
records. A patient that agrees to modified fo llow-up is not consi dered to have wi thdrawn from  the 
study .
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 41of 95Restart of rando mised IP is always encouraged. Even if a premature treatment discont inuat ion visit  
(PTDV) was completed due to discont inuat ion of IP, this shoul d not prevent the patient to return 
to randomised IP if deemed appropriate.
7.[ADDRESS_536742] be taken if a patient fails to return to the clinic for a required study 
visit:
The site must attempt to contact [CONTACT_424626].
Before a patient is deem ed potentially  lost to follow up, the Invest igator or designee must 
make every  effort to regain contact [CONTACT_72981], e.g. repeat telephone 
calls, certified letter to the pati ent´s last known mailing address or l ocal equivalent methods. 
These contact [CONTACT_23526]’s medical record.
Efforts to reach the patient should continue unt il the end of the study. Informat ion regarding 
vital status shoul d always be collecte d if possible.
7.3 Withdrawal from the study
Patients are free to withdraw fro m the study at any time (IP and assessments), without prejudice to 
further treatm ent. Wi thdrawal of consent shoul d only occur if the pat ient has received appropriate 
inform ation about and does not agree to any kind of further assessments or contact, including 
modified follow up options (see Section 7.1.2 ). Discontinuat ion of IP in itself is not considered 
withdrawal  of consent.
Withdrawal of consent must be ascertained and docum ented in writing by [CONTACT_424627].
A pat ient who withdraws fro m the study will always be asked about the reason(s) and the presence 
of any AE. The Invest igator wil l follow up AEs reported outside of the clinical study .
If a patient withdraws from participati on in the study , then his/her enrolment and rando misat ion 
codes cannot be reused. Withdrawn pat ients will not be replaced. If the pat ient withdraws consent 
for disclosure of future information, the sponsor may  retain and continue to use any  data collected 
before such a withdrawal o f consent.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 42of 95To ensure validit y of study data, it is very important to collect as much data as possible throughout 
the study  and especi ally vital status (dead or alive) at study  closure (also for patients who have 
withdrawn their informed consent). The Invest igator will therefore attempt to collect information 
on all patients’ vital status from publicly  available sources at study closure, even if informed 
consent has been withdrawn, in compliance with local privacy  laws/practices.
8. STUDY ASSESSMENTS AND PROCEDURES
Study  procedures and their timing are summarised in the SoA (see Section 1.1).
An E lectroni c Data Capture (EDC) system will be used for data collection and query handling. The 
Invest igator will ensure that data are recorded in the eCRFs as specified in the study  protocol  and 
in accordance wit h the eCRF instructions provided.
The Invest igator ensures t he accuracy, co mpleteness, legibilit y, and timeliness o f the data recorded 
and of the provisio n of answers to data queries according to the Clinical Study  Agreement. The 
Invest igator will sign the completed eCRFs. A copy  of the completed eCRFs will be archived at 
the study  site.
All screening evaluations must be completed and reviewed to confirm that potential pat ients meet 
all eligibilit y criteria. The Invest igator will maintain a screening log to record details of all patients 
screened and to confirm eli gibili ty or record reasons for screening failure, as applicable.
Procedures conducted as part of the patient’s routine clinical management (e.g. LVEF assessment) 
and obtained before signing of the ICF may be utilised for screening or baseline purposes pro vided 
the procedures met the protocol -specified criteria.
Adherence to the study  design requi rements, including those specified in the SoA, is essential and 
requi red for study conduct.
8.1 Enrolment Period
8.1.1 Visit 1, Enrolment (Day -21 to Day -1)
Enrolment of hospi[INVESTIGATOR_424589].
At enrolment the fo llowing assessments and procedures will be co mpleted:
 The patient signs the ICF
-Patients who agree to the optional sampling of blo od for genetic research will 
provi de thei r consent
 The invest igator assesses patient’s eligibilit y criteria and reviews concomitant 
medicat ions, rel evant m edicat ions will be recorded in the eCRF 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 43of 95!The patient will be enrolled and assigned an E-code in IxRS assuming 
inclusion/exclusion criteria are met
!Demography and relevant medical history (including prior cardiac imaging 
assessments) will be recorded
!A physical examination will be conducted
!NYHA Functional Classification will be evaluated and recorded
!12-lead ECG will be recorded
!Vital signs (BP, pulse), height and weight will be assessed and recorded
Blood samples will be taken for NT-proBN P, creatinine (for calculation of eGFR) and 
HbA1c assessment (central laboratory)
8.2 Treatment period
8.2.1 Visit 2, Randomisation (Day 1)
Prior to Visit 2, the investigator will assess elig ibility based on the central laboratory assessments 
from Visit 1. Patients not eligible will be  considered screen failures and s hould not continue to 
Visit 2.
Randomisation of hospi[INVESTIGATOR_424590].
At randomisation, the following assessments and procedures will be completed:!Medical history (including cardiac imaging assessments) will be re-assessed
!A physical examination will be conducted
!A pregnancy test for women of child-bearing potential will be donelocally with a 
dipstick provided by [CONTACT_424628]
!Vital signs (BP, pulse) will be assessed and recorded
!NYHA Functional Classification will be evaluated and recorded
!The investigator will re-assess the inclusion and exclusion criteria
!KCCQ, PGIS and EQ-5D-5L questionnaires will be completed
!Review of concomitant medication and recording of relevant medications
! If the patient has experienced any SAEs since last visit, this will be recorded in the eCRF
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 44of 95 Randomisat ion 1:1 ratio to IP (either dapagliflozin at 10 mg or placebo) will be done in 
IxRS
 IP will be dispensed via IxRS to the patient. The patient will be instructed to take the IP 
in accordance with protocol  without interrupti ons, and to bring all dispensed bottles to 
all study  visits
 Patients who have consented to sampling for genetic research, will provide a blood 
sample
8.2.2 Visit 3 (Day 30; ±7 days):
At Visit 3, the fo llowing assessments and procedures will be conducted:
 KCCQ and PGIS questionnaires will be completed
 NYHA Funct ional Classificat ion will be evaluated and recorded
 Vital signs (BP, pulse) will be assessed and recorded
 Review and updating of concomitant medication and recording of relevant medications
 Review and recording o f any cardiac and HF related procedures
 Review of potential efficacy  and safet y events including COVID -19 testing results
 If the patient has experienced any potential endpoints, SAEs, DAEs and/or amputations, 
adverse events (AEs) leading to amputation and potential risk factor AEs for amputations 
affecting lower limbs since the last visit, this will be recorded in the eCRF
 Blood sam ples will be taken for creatinine (for calculat ion of eGFR) assessment 
(central  laboratory )
8.2.3 Visit 4 (Day 120 ±7 days):
At Visit 4, the fo llowing assessments and procedures will be conducted:
 KCCQ and PGIS questionnaires will be completed
 NYHA Funct ional Classificat ion will be evaluated and recorded
 Review and updating of concomitant medication and recording of relevant medications
 Review and recording o f any cardiac and HF related procedures
 Review of potential efficacy  and safet y events including COVID -19 testing results
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 45of 95 If the patient has experienced any potential endpoints, SAEs, DAEs and/or amputations, 
adverse events (AEs) leading to amputation and potential risk factor AEs for amputations 
affecting lower limbs since the last visit, this will be recorded in the eCRF.
 Blood sam ples will be taken for creatinine (for calculat ion of eGFR) assess ment 
(central  laboratory )
 IP will be dispensed via IxRS to the patient. Drug accountabilit y of the returned IP will 
be checked. The patient will be instructed to take the IP in accordance with protocol and 
without interruptions
8.2.4 Visit 5 (Day 240 ±7 days)
At Visit 5, the fo llowing assessments and procedures will be conducted:
 KCCQ, PGIS and EQ -5D- 5L questionnaires will be completed
 NYHA Funct ional Classificat ion will be evaluated and recorded
 Review and updating of concomitant medication and recor ding of relevant medications
 Review and recording o f any cardiac and HF related procedures
 Review of potential efficacy  and safet y events including COVID -19 testing results
 If the patient has experienced any potential endpoints, SAEs, DAEs and/or amputations, 
adverse events (AEs) leading to amputation and potential risk factor AEs for amputations 
affecting lower limbs since the last visit, this will be recorded in the eCRF.
 IP will be dispensed via IxRS to the patient. Drug accountabilit y of the returned IP will 
be checked. The patient will be instructed to take the IP in accordance with protocol and 
without interruptions.
8.2.5 Visit 6 (Day 360 ±7 days)
At Visit 6, the fo llowing assessments and procedures will be conducted:
 Vital signs (BP, pu lse), and weight will be assessed and recorded
 Review and updating of concomitant medication and recording of relevant medications
 Review and recording o f any cardiac and HF related procedures
 Review of potential efficacy  and safet y events including COV ID-19 testing results
 If the patient has experienced any potential endpo ints, SAEs, DAEs and/or 
amputati ons, adverse events (AEs) leading to amputation and potential risk factor AEs 
for amputati ons affecting lower limbs since the last visit, this will be recorded i n the 
eCRF.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 46of 95 IP will be dispensed via IxRS to the patient. Drug accountabilit y of the returned IP will 
be checked. The patient will be instructed to take the IP in accordance with protocol and 
without interruptions.
 Blood sam ples will be taken for creatinine (for calculat ion of eGFR) assessment 
(central  laboratory )
8.2.6 Visit 7 and onwards (Day 480 and every 120 days ±14 days)
At visit 7 and subsequent visit s, the fo llowing assessments and procedures will be conducted:
 Review and updating of concomitant medication and recording of relevant medications
 Review and recording o f any cardiac and HF related procedures
 Review of potential efficacy  and safet y events including COVID -19 testing results
 If the patient has experienced any potential endpo ints, SAEs, DAEs and/or 
amputati ons, adverse events (AEs) leading to amputation and potential risk factor AEs 
for amputati ons affecting lower limbs since the last visit, this will be recorded in the 
eCRF.
 IP will be dispensed via IxRS to the patient. Drug accountabilit y of the returned IP will 
be checked. The patient will be instructed to take the IP in accordance with protocol and 
without interruptions.
 Starti ng from Visit 6, vital signs (BP, pulse), and weight assessment as well as blood 
samples collection for creatinine (for calculat ion of eGFR) will be repeated every 12 
months -on Visit 6, Visit 9and Visit 12.
8.2.7 Premature Treatment Discontinuation Visit
Patients who prematurely and perm anent ly discontinue treatm ent with IP should return for a 
prem ature treatm ent discont inuat ion visit (PTDV), which will be done as soon as possible after last 
dose of IP. The following assessments and procedures will be cond ucted:
 KCCQ, PGIS and EQ -5D-5L questionnaire will be completed
 NYHA Funct ional Classificat ion will be evaluated
 Vital signs (BP, pulse) and weight will be assessed and recorded
 Review and updating of concomitant medication and recording of relevant medications
 Review and recording o f any cardiac and HF related procedures
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 47of 95 Review of potential efficacy  and safet y events including COVID -19 testing results
 If the patient has experienced any potential endpoints, SAEs, DAEs and/or amputations, 
adverse events (AEs) leading to amputation and potential risk factor AEs for amputations 
affecting lower limbs since the last visit, this will be recorded in the eCRF
 Drug accountabilit y of the returned IP will be checked
Patients who discont inue treatm ent prem aturely shoul d attend all study  visits according to plan, 
including the study  closure visi t (SCV). Pati ents may  re-start treatm ents if assessed as appropriate 
by [CONTACT_24342]. For further details regarding discontinuations from IP, please see Section 7.1.
8.2.8 Study Closure Visit
A primary  analysis censoring date (PACD) will be declared based on the rate of accrued endpoints. A 
study  closure visit (SCV) will be scheduled within 6 weeks of the PACD. All patients (including any 
patients who have discontinued treatment with IP) should return for this visit.
The patient will stop taking IP at the SCV. Remaining IP will be collected at that time and drug 
accountabilit y will be checked. The fo llowing assessments and procedures will be conducted:
 KCCQ, PGIS and EQ -5D-5L questionnaire will be completed
 NYHA Funct ional Classificat ion will be evaluated
 A physical examinat ion will be conducted
 Vital signs (BP, pulse) and weight will be assessed and recorded.
 Review and updating of co ncomitant medication and recording of relevant medications
 Review and recording o f any cardiac and HF related procedures
 Review of potential efficacy  and safet y events including COVID -19 testing results
 If the patient has experienced any potential endpoints, SAEs, DAEs and/or amputations, 
adverse events (AEs) leading to amputation and potential risk factor AEs for amputations 
affecting lower limbs since the last visit, this will be recorded in the eCRF
 Drug accountabilit y of the returned IP will be checked
8.2.9 Unscheduled visits
An unscheduled on-site or telephone visit may occur in-between scheduled on-site visits (for 
example assessment of potential endpo int events or safet y events).
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 48of 958.3 Efficacy assessments
8.3.1 Efficacy event capture
Efficacy events (i.e. death, hospi [INVESTIGATOR_424591]) will be collected by [CONTACT_424629]. All potential efficacy events should be recorded as 
an AE and on additional event modules in the eCRF. If the potenti al efficacy  event fulfils SAE 
criteria (see Appendix B 2) the si te is to record and report these events to the sponsor or desi gnee 
within t imelines described in Section 8.6.
NYHA classificat ion will be done by [CONTACT_424630]. PROs will be 
collected for all patients throughout the study period via a hand -held electroni c device. All-cause 
hospi [INVESTIGATOR_424592] m SAE reports.
8.3.2 Efficacy event adjudication
A Clinical Events Adjudicat ion (CEA) Committee will be established for this trial and adj udicate 
primary  efficacy  events in accordance with adjudication criteria detailed in the CEA charter.
Events to be adjudicated include components of the primary efficacy  endpo int: deaths, 
hospi [INVESTIGATOR_424593], and urgent HF visit s. All deaths will be adjudicated to determine if they are 
CV or non -CV deaths. All adjudicat ion will be done on an ongoing basis throughout the trial.
8.3.3 Clinical Outcome Assessments (COA)
A COA is any assessment that may be influenced by [CONTACT_424631], judgement, or motivat ion and 
may support either direct or indirect evidence of treatment benefit. Patient Reported Outcomes 
(PROs) is one of the types of COAs. A PRO is any report of the status of a patient’s healt h condition 
that comes directly from the patient, without interpretati on of anyone else. PROs have beco me a 
significant endpo int when evaluat ing benefit/risk of treatments in clinical trials. The following 
PROs will be co llected: KCC Q, PGIS and EQ-5D- 5L (see Appendix I , Appendix K , Appendix L ).
PROs will be collected for all patients throughout the study  period via a hand -held electroni c 
device. See study  of assessment (See Table1 ) for the timing of collecti on. The ePRO devices shoul d 
be administered prior to first dose at visit 2/rando misat ion. Site staff shoul d stress that the 
inform ation is confident ial.
[IP_ADDRESS] KCCQ
The Kansas City Cardi omyopathy Quest ionnaire (KCCQ) is a 23-item, self -administered disease 
specific instrument and has shown to be a valid, reliable and responsive measure for patients with 
HF ( Greene et al  2018 , Spertus et al  2005 ). The KCCQ was devel oped to i ndependent ly measure 
the patient’s percept ion of their health status, which includes heart failure-related symptom s 
(frequency, severit y and recent change), impact on physical and social funct ion, self-efficacy  and 
knowl edge, and how their heart failure impacts their qualit y of life (QOL). Scores are transformed 
to a range of 0- 100. Higher scores represent a better outcome.
The KCCQ tool quant ifies the fo llowing six (6) distinct dom ains and two (2) summary scores:
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 49of 95 KCCQ Symptom  Dom ain quantifies the frequency and burden of clinical  symptom s in 
heart failure, including fatigue, shortness of breath, paroxy smal nocturnal  dyspnea and 
patients’ edema/swelling. An overall symptom  score is generally  used in analyses; 
subscale scores for both frequency and severi ty are also available. The total symptom 
Score incorporates the symptom domains into a single score
 KCCQ Physical Functi on Domain measures the limitat ions patients experience, due to 
their heart failure symptom s, in performing routine activities. Activities are commo n, 
gender -neutral, and generalizable across cultures, while also capturing a range of 
exert ional requirements
 KCCQ Qualit y of Life Do main is designed to reflect patients’ assessment of their 
qualit y of life, given the current status of their heart failure
 KCCQ Social Limitation Domain quantifies the extent to which heart failure symptoms 
impair patients’ ability to interact in a number of gender -neutral social activities
 KCCQ Self-efficacy Domain quant ifies patients’ percepti ons of how to prevent heart 
failure exacerbations and manage complications when they arise. This scale is not 
included in the summary  scores
 KCCQ Symptom  Stabilit y Domain measures recent changes in pat ients’ symptoms; their 
shortness of breath, fatigue or swelling. It compar es patients frequency of heart f ailure 
symptoms at the time of com pleting the KCCQ with thei r frequency [ADDRESS_536743] interpretabl e as a baseline assessment of the stabilit y of 
patients’ symptoms at the start of a study and shortly thereafter, as a measure of the acute 
response to treatment. This dom ain is not i ncluded in the summary scores.
 Clinical Summary Score includes total symptom and physical funct ion scores to 
correspond with NYHA Classificat ion
 Overall Summary  Score includes the total symptom, physical funct ion, social 
limitations and qualit y of life scores
[IP_ADDRESS] Patient Global I mpression of Severity (PGIS)
The PGIS item is included to assess how a patient perceives his/her overall current severit y of heart 
failure symptom s. Patients will choose from response options from “no symptom s” to “very 
severe”.
[IP_ADDRESS] EuroQoL five -dime nsional five -level questionnaire (EQ -5D-
5L)
The EQ-5D- 5L is a self-reported questionnaire that is used to derive a standardized measure of 
healt h status, also referred to as a utility score. EQ-5D- 5L utility scores are widely accepted by 
[CONTACT_424632].
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 50of [IP_ADDRESS] Administration of electronic PROs
Each site must allocate the responsibilit y for the administration of the ePROs to a specific 
individual and, if possible, assign a backup person to cover if that individual is absent. A key aspect 
of study  success is to have high PRO compliance. Therefore, it is essent ial to follow SoA and that 
sites make sure the device is charged and fully functional at all t imes in order to minimize missi ng 
data.
It is important that the site staff explains the value and relevance o f PRO data: to hear direct ly fro m 
patients how they  feel. The fo llowing best practice guidelines should be fo llowed:
 Patient must not receive help from relatives, friends, or site personnel to answer or 
clarify the PRO questi onnai res in order to avoi d bias. If a pati ent uses visual aids (e.g., 
spectacl es or contact [CONTACT_13276]) for reading and does not have them at hand, the patient will 
be exempted fro m completing the PROs quest ionnaires on that vi sit
 Before any  other study  procedures are conducted at a given visit (except the Visit 2: 
eligibilit y confi rmation before the KCCQ)
 Before being seen by [CONTACT_3170]
 PRO questionnaires must be completed by [CONTACT_424633]
 The appo inted site personnel shoul d also stress that the informat ion is confident ial. 
Therefore, if the pati ent has any medical probl ems, he or she shoul d discuss them wi th 
the doctor or research nurse separately fro m the ePRO assessment
 The appointed site personnel must show patients how to use the ePRO device, in 
accordance with the instructions provided
 The appo inted site personnel shoul d remind patients that there are no right or wrong 
answers, and the patient should be given sufficient time to complete the PRO 
questionnaires at his/her own speed
If a site is affected by [CONTACT_4113] -[ADDRESS_536744] ion of 
ePRO is an alternative solution to maintain continui ty of the assessments. The details of the 
procedure w ill be provided in a separate instruction.
If the patient is unable to read the questionnaire (e.g., is blind or illiterate), the patient will be 
exempted fro m completing the PRO questi onnaires and may still parti cipate in the study . Pati ents 
exempted in this regard should be flagged appropriately by  [CONTACT_424634] .
8.[ADDRESS_536745] ivities (Table 1).
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 51of 958.4.1 Physical examinations
A physical examinat ion will be perform ed at the time- points specified in Table 1andinclude an 
assessment of the fo llowing: general appearance, respi [INVESTIGATOR_424594] (including 
oedem a) and abdo men.
The assessmen t dates will  be recorded in the eCRF.
8.4.2 Vital Signs
 Pulse and BP will be measured twice at all applicable visits, and all measurements will 
be recorded in the eCRF.
 The measurements shoul d be done before any blood sampling. The measurements will 
be assessed in a sitting posit ion with a completely automated device. Manual techniques 
will be used only if an automated device is not available.
 The m easurements shoul d be preceded by [CONTACT_2669] [ADDRESS_536746] in a 
quiet setting wi thout di stracti ons (e.g., television, cell phones).
8.4.3 Electrocardiogram
A 12-lead ECG (standard ECG with a paper speed of 25-50 mm/second covering at least 6 
sequent ial beats) will be recorded at baseline (Visit 1) after the patient has been lying down to re st 
for at least 5 minutes, to confirm presence or absence of atrial fibrillat ion/flutter at enrolment. Heart 
rate and heart rhythm will be reported in the eCRF. The baseline ECG shoul d be stored and be 
made available upon request for adjudicat ion purposes
8.4.4 Safety laboratory assessments
Serum  creatinine will be co llected for calculat ion of eGFR using CKD- EPI [INVESTIGATOR_154510] (Levey  et al  
2009 ).
8.4.[ADDRESS_536747] and resul t (posi tive/negat ive) should be recorded 
in the eCRF.
8.4.6 Other clinical assessments
[IP_ADDRESS] Body weight and height
The pati ent’s body  weight will  be measured with light clothing and no shoes. If the patient has a 
prostheti c limb, this shoul d be consistent ly worn during all weight measurements. The patient’s 
height will be measured at Visi t 1, wi th no shoes. The weight and height will  be recorded in the 
eCRF.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 52of 958.[ADDRESS_536748] ion.
The definit ions of an AE or SAE can be found in Appendix B .
AE will be reported by [CONTACT_102] (or, when appropriate, by a caregiver, surrogate, or the patient's 
legally authorised representative).
The Invest igator and any designees are responsible for detecting, docum enting, and recording 
events that meet the definit ion of a SAEs and DAEs, amputation and events potentially p lacing the 
patient at ri sk for a lower limb amputati on (preceding events). F or informat ion on how to foll ow-
up AEs see Section 8.5.3 .
8.5.1 Method of detecting AEs and SAEs
Care will be taken not to introduce bias when detecting SAEs or DAEs. Open -ended and non-
leading verbal questioning of the pat ient is the preferred method to inquire about AE occurrences.
Safety informat ion on SAEs and DAEs, amputati ons, adverse events (AEs) leading to amputation 
and potenti al risk factor AEs for amputations affecting lower limbs will be collected and entered 
into eCRFs by  [CONTACT_103460].
If the potential efficacy event fulfils SAE criteria (see Appendix B 2) the site is to record and report 
these events to the Sponsor or designee within timelines described in Section 8.6.1 .
[IP_ADDRESS] Adverse events (AEs) leading to amputation and potential risk factor AEs for 
amputations affecting lower limbs (“preceding events”)
To ensure that data on amputati ons is system atically collected, amputati ons and underlying 
condi tions relevant to amputation will be recorded on a specific eCRF page. The adverse event 
leading to amputation should be recorded in the eCRF as AE/SAE.
In addit ion to am putati on, non -serious and serious events potentially  placing the pati ent at ri sk for 
a lower limb amputati on (“preceding events”) shoul d also be recorded in the eCRF as AE/SAE 
whether or not an amputati on has taken place. The lower limb amputati on “preceding events” of 
interest include diabet ic foot related condi tions, vascular, volume deplet ion, wounds/injury/trauma, 
infect ion and neuropathy. If any o f these or other potentially relevant events have occurred, relevant 
information must be provided (this will be collected on a dedicated eCRF page -for details see 
eCRF instruction)”.
[IP_ADDRESS] Capture of DKA events
For SAEs or DAEs reported by [CONTACT_424635] (DKA -see definit ion 
below) addit ional information will be recorded on specific eCRF pages in addit ion to the AE/SAE 
form. All potenti al events of DKA will be submi tted to an independent DKA Adjudicat ion 
Committee, see Secti on [IP_ADDRESS].2 )
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 53of [IP_ADDRESS].1 DKA definition
A diagnosis of Diabet ic Ketoacidosis shoul d only be made in a clinical setting consistent with DKA 
(based on patient history , symptoms, and physical  exam) and in the absence of more likely 
alternat ive diagnoses and causes of acidosi s (such as lactic acidos is). The following biochemical 
data should support diagnosis:
Ketonaemia ≥3.0 mmo l/L and/or significant ketonuri a (more than 2+ on standard urine 
sticks)
At least one of the fo llowing criteria suggest ing high anio n gap m etabo lic acidosis:
Arterial or Venous pH ≤7.3
Serum  bicarbonate ≤18 mEq/L
Anio n gap [Na –(Cl + HCO3)] >10
[IP_ADDRESS].[ADDRESS_536749] ion of DKA informat ion, handling, 
adjudicat ion criteria and reporting of these events.
[IP_ADDRESS] Capture of cardiac ischaemic even ts and stroke
For my ocardial  infarct ions, unstable angina and stroke addit ional information will be recorded on 
specific eCRF pages in addit ion to the AE/SAE form.
The diagnosis of stroke, MI and unstable angina shoul d be made according to standard clinical 
practi ce and align wit h the definit ion for stroke in the standardised definit ions for endpo ints (Hicks 
et al 2018 )described in Appendix C .
[IP_ADDRESS] Capture of Major hypoglycaemic events
A major hypoglycemic event is defined as an event that i s characteri zed by [CONTACT_424636]/or 
physical status, any symptoms of severe impairment in consciousness or behavior, that require 
external assistance of another person for treatm ent of hypoglycemia and recovery , to actively 
administer carbohydrates, glucagon, or take other corrective actions.
Plasma glucose concentrati ons may not be available during a hypoglycaemic event, but 
neuro logical recovery  following the corrective actions is considered sufficient evidence that the 
event was induced by  a low pl asma glucose concentration. Major hy poglycaemic epi[INVESTIGATOR_424595].
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 54of [IP_ADDRESS] Capture of additional laboratory values
Any addit ional safet y laboratory  assessments during the study period, including creat inine, will be 
obtained per the Investi gator’s medical judgment in the course of standard care using local 
laboratories. Laboratory  values woul d be recorded only on SAE eCRFs as part of narrat ive 
inform ation, per the Invest igator’s judgment.
8.5.2 Time period and frequency for collecting AE and SAE information
Non-serious adverse events as defined per protocol will be co llected from rando misat ion (Visit 2), 
throughout the treatment period unti l and including the patient’s last visit (the study closure visit). 
Serious adverse events are recorded from the time of signing o f informed consent form throughout 
the treatment period until and including the patient's last visit.
All SAEs will be record ed and reported to the sponsor or designee within 24 hours, as indicated in 
Appendix B .The Investigator will submit any updated SAE data to the sponsor within
24 hours of it being available.
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Appendix B .
8.5.3 Follow -up of AEs and SAEs
After the initial AE/SAE report, the Investigator is required to proactively follow each patient at 
subsequent visit s/contacts. All  SAE and events of  amputati on and potenti al preceding events will 
be followed until reso lution, stabilizat ion, the event is otherwise explained, or th e patient is lost to 
follow-up.
Any AEs that are unresolved at the patient’s last visit in the study  are followed up by [CONTACT_72989], but without further recording in the CRF. 
[COMPANY_008] retains the right to request addit ional information for any patient with ongoing 
AE(s)/SAE(s) at the end of the study , if judged necessary .
8.5.[ADDRESS_536750] for each AE;
 AE (verbat im)
 The date when the AE started and stopped
 Maximum intensit y (mild/m oderate/severe)
 Whether the AE is serious or not
 Invest igator causalit y rating against the Investigat ional Product(s) (y es or no)
 Action taken with regard to IP
 Outcom e
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 55of 95In addit ion, the fo llowing vari ables will be collected for SAEs:
 Date AE m et cri teria for seri ous AE
 Date Invest igator became aware of serious AE
 AE is seri ous due to
 Date of hospi[INVESTIGATOR_72913]
 Date of discharge
 Probable cause of death
 Date of death
 Autopsy  performed
 Causalit y assessment in relation to Study  procedure(s) and/or other medicat ion
 Descript ion of AE
8.5.[ADDRESS_536751] igator will assess causal relati onship between the IP and each AE and answer ‘yes’ or 
‘no’ to the question ‘Do you consider that there is a rea sonable possibilit y that the event may have 
been caused by [CONTACT_33159]?’
For SAEs, causal relationship will also be assessed for other medicat ion and study  procedures. 
Note that for SAEs that could be associ ated with any study  procedure the causal relationship is 
implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix B to the Clinical Study 
Protocol .
8.5.6 Adverse events based on signs and symptoms
All AEs spontaneously reported by [CONTACT_424637] e open question from 
the study personnel: ‘Have you had any healt h probl ems since the previous visit/you were last 
asked?’ or revealed by [CONTACT_424638] 8.5.[ADDRESS_536752] ing AEs, the recording of diagnoses is preferred 
(when possible) to recording a list of signs and symptom s. However, if a diagnosis is known and 
thereare other signs or symptom s that are not generally part of the diagnosis, the diagnosis and 
each sign or symptom will be recorded separately .
8.5.7 Adverse events based on examinations and tests
The resul ts from the Clinical Study  Protocol  mandated vital signs and laboratory  values will be 
summarised in the clinical study  report. Deterioration as compared with baseline in protocol -
mandated vital signs should therefore only be reported as AEs if they fulfil any of the SAE criteria 
or are the reason for discontinuati on of treatm ent with the IP. If deteri oration in a vital sign is 
associ ated with clinical signs and symptoms, the sign or symptom will be reported as an AE if the y 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 56of 95fulfil any of the SAE criteria or are the reason for discont inuat ion of treatment of IP, and the 
associ ated vi tal sign will  be considered as addi tional informat ion.
8.5.8 Disease -under study (DUS) (not applicable)
8.5.9 Disease progression (not applicable)
8.[ADDRESS_536753], or to the study  procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study , then Invest igators or other si te personnel  inform the 
appropriate [COMPANY_008] representatives within one day i.e., immediately but no later than [ADDRESS_536754] igators or other site personnel indicate an AE is serious in the EDC system , an 
autom ated em ail alert is sent to the designated [COMPANY_008] representative.
If the EDC system  is not available, then the Investigator or other study  site staff  reports a SAE to 
the appropriate [COMPANY_008] representative by [CONTACT_756].
The [COMPANY_008] representative will advise the Investigator/study  site staff how to proceed.
Invest igators or other site personnel send relevant CRF modules by [CONTACT_324699].
For further guidance on the definit ion of a SAE, see Appendix B of the Clinical Study  Protocol .
[IP_ADDRESS] Reporting of SAEs considered to be potential endpoints
In order to avoid unnecessary unblinding of efficacy endpo int events, certain SAEs which are also 
potenti al endpo ints (i.e., fatal AEs and HF events) will not be reported to health authori ties. Clinical 
data for the above mentioned events will be recorded as AEs/SAEs as well as on separate event 
forms in the eCRF. Recording o f a suspected endpoint should be done within the same timeframes 
as defined for SAEs (see Section 8.6.1 ).
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 57of 95In addi tion, fatal  AEs and potenti al HF endpoints will  be centrally  adjudicated by  [CONTACT_424639] (see Secti on 8.3.1 and 8.3.2 ). If adjudicat ion confirms the endpoint, the SAE will 
not be reported to health authori ties. However, if it is determined by [CONTACT_424640] a 
potenti al endpoint does not m eet the endpoint cri teria, the event will be reported (according to the 
timelines specified in Section 8.6.1 ) to AZ patient safet y data entry  site and if applicable to the 
healt h authorit ies (note that the clock starts when the adjudicat ion results are available).
8.6.[ADDRESS_536755] igator should inform the sponsor within 24 hours of learning o f the pregnancy. Abnormal
pregnancy outcom es (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies, 
ectopi c pregnancy) are considered SAEs.
[IP_ADDRESS] Maternal exposure
Women of childbearing potential  who are not using contracepti on as defined in Secti on 5.2; 
exclusio n criterion number [ADDRESS_536756] to hum an renal  maturati on, 
maternal exposure to dapagliflozin in rat studi es was associ ated with increased incidence and/or 
severit y of renal  pelvic and tubular dilatati ons in progeny .
There are no adequate and well-controlled studi es of dapagliflo zin in pregnant wom en. When 
pregnancy is detected, investigational product(s) should be discontinued.
8.6.3 Overdose
Dapaglifl ozin has been well tolerated at doses of up to 500 mg/day in single dose testing in healthy 
volunteers and up to 100 mg/day in repeat dose testing for 14 days in healthy volunteers and 
patients wi th T2D. Suspected single intake of  more than 50 tabl ets of  10 mg dapagliflo zin tablets 
or repeated intake of more than 10 tablets of 10 mg dapagliflozin tablets should be reported on the 
eCRF overdose module. If an overdose is suspected, monitoring of vital functions as well as 
treatm ent shoul d be perform ed as appr opriate.
For further information regarding overdose, refer to the IB.
 An overdose without associated symptoms is only recorded on the Overdose eCRF 
module
 An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the eCRF and on the Overdose eCRF module
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 58of 95If an overdose on an [COMPANY_008] IP occurs in the course of the study, then the invest igator or other 
site personnel inform  appropri ate [COMPANY_008] representatives immediately, or no later than [ADDRESS_536757] occur within 30 day s.
8.7 Pharmacokinetics (not applicable)
8.8 Pharmacodynamics (not applicable)
8.[ADDRESS_536758] ion 
and shipment and destruction of these samples can be found in Appendix D .
8.10 Biomarkers (not applicable)
8.11 Health Economics (not applicable)
9. STATISTICAL CONSIDERATIONS
9.1 Statistical hypotheses
For the primary  and secondary  endpoints, the following hypothesis will be tested at the 4.980 % 
2-sided level:
H0: HR [dapagliflozin:placebo] =1
versus
H1: HR [dapagliflozin:placebo] ≠[ADDRESS_536759] of care in reducing the composite of CV death and heart failure events 
(hospi [INVESTIGATOR_424567]). Two hypotheses will be tested simultaneously (i.e., dual 
primary  analyses) for the primary object ive: (1) in the full popul ation and in(2)an LVEF <60% 
subpopulation, with alpha allocated to each test. Originally, assuming a true hazard ratio (HR) of 
0.80 between dapagliflozin and placebo, using a two-sided alpha of 5%, 844 primary endpo int 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 59of 95events were targeted in order to provide a statistical power of 90% for the test of the primary 
composite endpo int. To allow testing for the dual primary analyses, alpha will be allocated to each 
test to ensure strong control of the overall type I error rate. The target number of patients with a 
primary  endpoint has been increased to [ADDRESS_536760] 70% of the events (i.e., approximately 780 events) will be available 
for the LVEF <60% subpopulat ion. To illustrate, assuming a true HR of 0.80, a two -sided alpha o f 
2.4% allocated to the LVEF <60% subpopul ation will resul t in a po wer of 80% to detect a treatm ent 
difference, whereas an alpha allocation of 1.5% to the full popul ation will resul t in 90% power. 
The final alpha split f or the dual primary analyses will be specified in the SAP prior to the planned 
interim analysis. This is based on an overall 1:1 allocation between dapagliflo zin and placebo.
The HR 0.80 was ori ginally  chosen as a conservative assumpti on based on the obse rved HR 0.72 
(95% confidence interval 0.50-1.04) for the composite of HF hospi [INVESTIGATOR_424596] -REG OUTCOME trial ( Fitchett et al 2016 ) and HR 0.61 
(0.46 -0.80) for patients with history  of HF in the CANVAS program (Rådho lm et al 2018 ) 
considering that these were post -hoc analyses in subgroups with limited documentation of baseline 
HF di agnosis, not characterised by  [CONTACT_424641].
The event rate assum ptions are based on sub analyses of the TOPCAT and I -PRESERVE studi es 
by [CONTACT_82724], NT -proBNP l evels, pri or hospi [INVESTIGATOR_424593], and T2D status (Pfeffer et 
al 2015 ,Kristensen et al 2015 ,Kristensen et al 2017 ). The original sample size calculatio n (~ 4700
rando mized patients) built on the assumpt ion of an annual event rate of  9% inthe placebo group 
for the majo rity of prevalent HFpEF patients, importantly all with NT -proBNP ≥300 pg/ml by 
[CONTACT_424642] n criterion. Addit ionally , a subgroup of patients due to be discharged or recently discharged 
from a HF hospi [INVESTIGATOR_72913] (here denoted ‘subacute’ patients) with a higher event rate is planned to 
be included. Assuming 20% of patients from the subac ute category  with an annual event rate of 
24% during the first year and 9% thereafter for the remainder of the study, the original sample size 
of [ADDRESS_536761] imated to provide the required number of 844 patients with a primary event 
during a recru itment period of  18 m onths and a minimum fo llow-up peri od of  15 m onths. 
Based on the ongoing blinded monitoring of event accrual (including the percentage of patients 
from the subacute category), the sample size is increased from original 4700 to approximately 6100 
rando mised patients. Accordingly , the recrui tment period is anticipated to increase from the 
original  18 months to 26 m onths. Recrui tment might be marginally prolonged in a few countri es 
to meet local targets. The study  is event driven a nd the number of patients or duration may further 
change.
With the same event rate assumpt ions as above, assuming 11% of patients from the subacute 
category , approximately 6100 patients are estimated to provide the requi red number of 1117 
patients with a primary  event during an anticipated recrui tment period of 26 mo nths and a minimum 
follow-up period of 13.5 months (total study  duration 39  months).
In addit ion, the expected number of patients who will be lost to fo llow-up is expected to be small; 
hence, these are not considered in the determinat ion of the sample size.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 60of 959.3 Populations for analyses
For purposes of analysis, the following populat ions are defined:
Table 5 Population for analysis
Population Description
Enrolled All patients who sign the ICF
Full Analysis Set (FAS)All patients who have been randomised to study treatment, irrespective
of their protocol adherence and continued participation in the study.
Patients will be analysed according to their randomised investigational
product assignment, irrespective of the treatment actually received. The
FAS will be considered the primary analysis set for the intention to
treat analysis of primary and secondary variables. A subset of the full 
analysis set consisting of patients with b aseline LVEF of <60% (or 
LVEF <60% subpopulation) will be analysed separately as part of the 
confirmatory statistical testing procedure.
Safety analysis setAll patients randomly assigned to Study treatment and who take at
least [ADDRESS_536762] ical analysis plan (SAP) will be developed prior to first patient randomi sed 
and any subsequent amendments will be documented, with final amendments finalised before
database lock. This section is a summary of the planned statistical analyses of the primary and 
secondary  endpoints. Any  deviat ions from  this plan will be reported in the clinical study report.
9.4.1 Efficacy analyses
[IP_ADDRESS] Analysis of the primary variable
The primary variable is the time from randomisation to first event included in the primar y 
composite endpo int. Two hypotheses will be tested simultaneously (i.e., dual primary endpo int 
analyses): (1) in the full populat ion and (2) in an LVEF <60% subpopulat ion, with alpha allocated 
to each test. The primary analysis will be based on the ITT principle using the FAS, including 
events occurring on or prior to th e PACD, adjudicated by  [CONTACT_424643].
In the analysis of the primary  composite endpo int, treatm ents (dapagliflozin versus placebo) will 
be compared using a Cox proporti onal hazards model with a factor f or treatm ent group, stratified 
by T2D status at randomisat ion. The p- value, HR and 95% confidence interval will be reported.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 61of 95The contribution of each component of the primary  composite endpo int to the overall treatm ent 
effect will be examined. Methods similar to those described for the primary  analysis will be used 
to separately analyse the time fro m rando misat ion to the first occurrence of each component of the 
primary  com posite endpoint. HR and 95% confidence intervals will be reported.
Kaplan -Meier estimates of the cumulative incidence to the first occurrence of any event in the 
primary  endpo int will be calculated and plotted, for overall analysis and for the individua l 
components.
[IP_ADDRESS] Analysis of the secondary variables
The outcome of all HF events (first and recurring) and CV death will be analysed by [CONTACT_424644] -
param etric proporti onal rates m odel (Lin et al 2000) to test the treatment effect and to quantify the 
treatm ent difference. The rate rati o and its 95% confidence interval and corresponding two-sided 
p-value wil l be presented. Thi s outcom e will also be analysed for the LVEF <60% subpopul ation 
within the mul tiple testing procedure as described in S ection9.2.
The analysis of change from baseline for KCCQ total symptom  score at 8 months will be further 
detailed in the stati stical analysis plan, e.g. wi th considerati on of  handling of  patients who di e. In 
addition to the secondary  endpo int, total symptom score, the overall summary  score, clinica l 
summary score and domain scores will be analysed. A responder analysis will also be perform ed 
(more details presented in the SAP).
The analysis of the endpo ints time fro m rando misati on to CV death and time to all -cause mortalit y 
will be analysed in the similar manner as the primary  variable.
[IP_ADDRESS] Subgroup analysis
Subgroup variables for the primary efficacy endpoint include demography, baseline disease 
characterist ics, baseline concomitant medications and others. Cox proporti onal hazard model
stratified for T2D with factors for treatm ent group, the subgroup variable and the interacti on 
between treatm ent and subgroup will be used to examine treatm ent effects within relevant 
subgroups separately . A test of  interacti on between rando mised treatment group and the subgroup 
variable will be perfo rmed in each Cox m odel. The p -values for the subgroup analyses will not be 
adjusted for mult iple comparisons as the tests are exploratory and will be interpreted descriptively. 
Treatment differences with 95% confidence intervals will be reported for each s ubgroup. HRs and 
CIs for overall  analysis and subgroups will be presented with forest plots as well. Further details 
of the subgroup analysis, including the list of subgroup variables, will be provided in the SAP.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 62of [IP_ADDRESS] Sensitivity analysis
Details of the sensi tivity analysis for the primary and secondary  endpoints will  be provi ded in the 
SAP.
9.4.[ADDRESS_536763] less of whether patients are on or off study  treatm ent.
9.4.3 Methods for multiplicity control
A closed testing procedure including a pre-specified hierarchical ordering of the primary  and 
secondary  endpoints will be utilised. The Type I error will be controlled at an overall two-sided 
5% level for multip licity across primary  and secondary  endpoints and in considerat ion of the 
planned interim analysis. With one interim analysis at 67% of events (see Secti on 9.5) the two-
sided significance level in fina l analysis, α, will be 4.980%. Statist ical significance will be assessed 
in two branches in a pre -specified order of the endpoints and populat ions which is further described 
in the SAP. The significance level α, will be spli t for the two primary  analyses, denoted α1and α2. 
If either of the tests of the primary endpo int in the full study  population and for LVEF <60% 
subpopulation is significant at respective levels α1and α2, the next hypothesis in the respect ive 
branch sequence will be tested at the same significance level. The exact split of alpha will be 
docum ented in an updated SAP before the interim analysis. If all hypotheses in one arm are 
rejected, the al pha will be recycled to the other branch. 
9.5 Interim analyses
An interim analysis is planned to be performed including approximately 67% of the target number 
of patients with adjudicated primary endpo int events (approximately 748 events) .There will in 
principle be one planned interim analysis for efficacy , with the possibili ty of the DMC to conduct 
subsequent interim analysis if they deem necessary. The significa nce level for final analysis will 
be determined by [CONTACT_424645]-Peto function based on the actual number of interim analyses. The 
interim analysis will assess superiorit y of dapagliflozin to pl acebo. The interim analysis will have 
a nominal two -sided alpha level  of 0.2%. At the interim  analysis, the primary  com posite endpoint 
will be tested in the fullstudy  popul ationat the specified alpha level. If superiorit y is achieved for 
the primary  endpoint, then the superi ority of dapagliflozin to pl acebo on CV d eaths will be tested
in the full study  popul ationat a two -sided level  of 0.2%. If CV death is significant, then an act ion 
is triggered whereby  [CONTACT_424646] y of the efficacy data and safet y data, to 
determine if benefit is unequivocal and overwhelming such that the DMC recommends ending the 
study .
In the initial versio n of the protocol , there was a planned futility analysis to be perform ed at the 
time of interim analysis. This futility analysis was removed, since formal testing was updated to 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 63of 95include both the LVEF <60% subpopulat ion and full study  population, and that this potentially 
creates complex scenarios related to fut ility and benefit in one, other or both populat ions.
9.5.1 Data monitoring committee (DMC)
An independent data monitoring commit tee (DMC) will be appo inted and will report to the 
Execut ive Commit tee. The DMC will be responsible for safeguarding the interests of the pati ents 
in the outcom e study  by [CONTACT_309566] y of the intervention during the study . The DMC will 
have access to the individual treatment codes and be able to m erge these wi th the collected study 
data while the study  is ongoing. A charter will be prepared to detail precise roles and 
responsibilit ies and procedures of the DMC.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 64of 9510. REFERENCES
Ambrosy et al [ADDRESS_536764] ives in hospi[INVESTIGATOR_424597]: regional and ethnic variation in patient characterist ics, management, and outcom es. 
Curr Heart Fail Rep 2014 Dec;11(4):416-27.
Borlaug and Paulus [ADDRESS_536765] ion fraction: pathophysio logy, diagnosis, 
and treatment. Eur Heart J 2011;32:[ADDRESS_536766] heart failure: the Lancet lecture. Lancet 2015;385:[ADDRESS_536767] ion fraction: current state and future di rections. JACC Heart Fail 
2014 Apr;2(2):97-112.
Cherney et al [ADDRESS_536768] of  the 
empaglifl ozin on arteri al stiffness and heart rate vari ability in subjects wi th uncom plicated ty pe 1 
diabetes m ellitus. Cardi ovasc Diabetol  2014;13:28.
Chilton et al 2015
Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin 
on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 
diabetes. Di abetes Obes Meta bo 2015;17:1180 -93.
Cook et al 2014
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart 
failure. Int J Cardio l 2014 Feb 15;171(3):368-76.
EMA Guidance 2016
EMA 2016; Guideline on clinical investigation of medicinal products for the treatment of chronic
heart failure (draf t), Committee for Medi cinal Products for Hum an Use (CHMP). 
EMA/CHMP/392958/2015.
FDA Draft Guidance for Industry 2016
Food and Drug Administration. Use of real -world evidence to support regulatory  decisi on-making 
for medical devices. Draft Guidance for Industry and Food and Drug Administrati on Staff. 16 
September 2016.
Fitchett et al 2016
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 65of 95Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel  S, Salsali A, et al. Heart failure outcom es 
with empaglifl ozin in patients with type 2 diabetes at high cardi ovascular risk: resul ts of the 
EMPA -REG OUTCOME®trial. Eur Heart J 2016;14;37(19):1526-34.
Greene et al 2018
Greene SJ, Mentz RJ, Felker GM. Outpatient Worsening Heart Failure as a Target for T herapy: A 
Review. JAMA Cardi ol. 2018 Jan 31. doi:10.1001/jamacardio.2017.5250. [Epub ahead of print] 
PubMed PMID: 29387880.
Hicks et al [ADDRESS_536769] 20, 2014.
Hicks et al 2018
Hicks KA, Mahaffey  KW, Mehran R, Ni ssen SE, et alCardio vascular and Stroke Endpoint 
Definit ions for Clinical Trials. J Am Co ll Cardio l 2018;71:1021 –34
Inzucchi et al 2012
Inzucchi SE, Bergenstal RM, Buse J.B, Diamant M, Ferrannini E, Nauck M et al. Management of 
hyperglycaemia in type 2 diabetes: a patient -centered approach. Posit ion statem entof  the American 
Diabetes Associ ation (ADA) and the European Associ ation for the Study  of Diabetes (EASD). 
Diabetes Care. 2012 Jun;35(6):[ADDRESS_536770],and Matthews David R. Management 
of Hyperglycemia in Type 2 Diabetes, 2015: A Patient -Centered Approach. Update to a Posit ion 
Statem ent of the Amer ican Diabetes Associ ation and the European Associat ion for the Study  of 
Diabetes. Di abetes Care 2015;38:140– 149
Iwaz et al 2016
Iwaz JA, Le E, Aramin H, Rom ero D, Iqbal N, Kawahara M, et al. New targets in the drug treatm ent 
of heart failure. Drugs 2016;79:187-201.
Kosibor od et al [ADDRESS_536771] igators and Study Group. Lower risk of heart failure and death in pat ients init iated on 
SGLT -2 inhibitors versus other gl ucose -lowering drugs: the CVD -REAL study . Circulati on 2017 
May 18. pii: CIRCULATIONAHA.117.029190. doi: 10.1161/CIRCULATIONAHA.117.029190. 
Kosiborod et al 2017b
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 66of 95Kosiborod M, Gause-Nilsson I, J Xu J, Sonesson C, Johnsson E. Efficacy and safety of and 
dapagliflozin in patients with type 2 diab etes mellitus concomitant heart failure. J Diabetes 
Complications 2017; 31 (7):1215-21.
Kristensen et al 2015
Kristensen SL, Jhund PS, Køber L, McKelvie RS, Zile MR, Anand IS, et al. Relative importance 
of history of heart failure hospi[INVESTIGATOR_31739] N-terminal Pro–B-type natriuretic peptide level as 
predictors of outcomes in patients With heart failure and preserved ejection fraction. JACC Heart 
Fail 2015 Jun;3(6):478-86.
Kristensen et al 2016
Kristensen SL, Preiss D, Jhund PS, Squire I, Ca rdoso JS et al. Risk related to pre–diabetes mellitus 
and diabetes mellitus in heart failure with reduced ejection fraction insights from prospective 
comparison of ARNI with ACEI to determine impact on global mor tality and morbidity in heart 
failure trial. Circ Heart Fail. 2016;9:e002560.
Kristensen et al [ADDRESS_536772] ion fraction: a report from  the I-Preserve Trial 
(Irbesartan in Heart Failure With Preserved E jection Fraction). Circulation. 201721;135(8):724-
35.
Lam et al 2011
Lam CSP, Donal E, Kraigher-Krainer E, Vasan RS. Epi[INVESTIGATOR_103419]. European Journal of Heart Failure 2011; 13: 18–28.
Lam et al 2020
Lam CSP, Voors AA, Ponikowski P, McMurray J JV, Solomon SD. Time to rename [CONTACT_424656]: heart failure with mildly reduced ejection fraction. European Heart Journal 2020; 41:2353-55.
Levey at al [ADDRESS_536773], Feldman HI et al. A new 
equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5; 150(9):604-12.
Lin et al 2000
Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of 
recurrent events. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2000; 
62(4):711–730.
Nauta et al [ADDRESS_536774] we learned about heart failure with mi drange ejection fraction one year after its 
introduction? European Journal of Heart Failure 2017; 19(12): 1569-1573.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 67of 95Neal et al 2017
Neal B, Perkovi c V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al, for th e CANVAS 
Program  Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 
diabetes. N Engl  J Med 2017; 377: 644-657.
Oktay et al 2013
Oktay  AA, Rich JD, Shah SJ. The emerging epi[INVESTIGATOR_424598]. Curr Heart F ail Rep 2013;10(4):401 -10.
Okumura et al 2016
Okum ura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, 
Zile MR, Solo mon SD, Packer M, McMurray JJ; PARADIGM -HF Invest igators and Committees*. 
Importance of Clinical Worsening of Heart Failure Treated in the Outpati ent Setti ng: Evidence 
From  the Prospective Com parison of ARNI Wi th ACEI to Determine Impact on Gl obal Mortali ty 
and Morbidit y in Heart Failure Trial (PARADIGM -HF). Circulat ion. 2016 Jun 7;133(23):2254 -62. 
doi:
10.1161 /CIRCULATIONAHA.115.020729. Epub 2016 Apr 20. PubMed PMID: 27143684. 
Ott et al [ADDRESS_536775] of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulat ion. 
Cardi ovasc Diabetol  2017;16:26.
Pfeffer et al [ADDRESS_536776] (TOPCAT) Trial. Circulatio n. 2015;131:34-42.
Rådholm et al 2018
Rådholm K, Figtree, Perkovic V, Solomon SD, Mahaffey KW, et al. Canagliflozin and Heart 
Failure in Ty pe 2 Di abetes Mellitus: Results From the CANVAS Program  (Canagliflozin 
Cardi ovascular Assessment Study ). Circulat ion. 2018;137 
https://doi .org/10.1161/CIRCULATIONAHA.118.[ADDRESS_536777] ion and glycemic control  in patients with early -stage 
type 2 diabetes mellitus: DEFENCE study . Cardi ovasc Diabetol  2017;16:84. DOI 10.1186/s12933 -
017-[ADDRESS_536778] inpatient and outpati ent 
heart failure event in a heart failure clinical trial: MADIT -CRT. Eur J Heart Fail. 2014 
May;16(5):560- 5. doi: 10.1002/ej hf.71. Epub 2014 Feb 27. PubMed PMID: 24578164.
Solomon et al 2005
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 68of 95Solomon SD, Anavekar N, Skali H, McMurray  JJ, Swedberg K, Yusuf S, Granger CB, Michelso n 
EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduct ion in Mortali ty 
(CHARM) Investigators. Influence of ejection fraction on cardi ovascular outcom es in a broad 
spectrum of heart failure patients. Circulat ion 2005 Dec 13;112(24):3738-[ADDRESS_536779] igators and Committees; Angiotensin -Neprilysin 
Inhibit ion in Heart Failure with Preserved Ejection Fract ion. The New England Journal of 
Medicine 2019; 381:1609-1620.
Solomon et al 2020
Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, Rouleau JJ, Pfeffer 
MA, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Arango JL, 
Vinere anu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray 
JJV; Sacubi tril/Valsartan Across the Spectrum  of Eject ion Fract ion in Heart Failure. Circulat ion 
2020; 141:352-361.
Spertus et al [ADDRESS_536780] MW, Heidenreich PA, Krumho lz HM, Jones P, et al. Moni toring 
clinical changes in patients with heart failure: A comparison of methods. Am Heart J 
2005;150:[ADDRESS_536781] ian, Alpert Joseph S., Jaffe Allan S., Simoons Maarten L, Chait man ,White Harvey 
D. Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal 
Definit ion of Myocardial  Infarcti on. Third Universal Definit ion of Myocardial  Infarction. Global 
Heart Vol : 7 (4), 2012 Page: 275 -295
Wanner et al 2016
Wanner Christoph; Inzucchi, Silvio E.; Lachin, John M; Fitchett, David; von Eynatten, 
Maximilian. Cardio metabolic Risk Factor Changes Observed in Diabetes Prevent ion Programs in 
US Settings: A Systemat ic Review and Meta- analysis. New England Journal  of Medicine Vol: 375 
(4) 2016 Page: 323 - 334
Zannad et al 2014
Zannad F Garcia AA, Anker SD Armstrong PW Calvo G et al. Clinical outcome endpo ints in heart 
failure trials: a European Society of Cardiology Heart Failure Associ ation consensus docu ment. 
Eur J Heart Failure 2013;15:1082 –94.
Zinman et al 2015
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E et al. Empagliflozin, cardiovascular 
outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117 -2128.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 69of 9511. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
Appendix A Regulatory, ethical and study oversight considerations
A 1 Regulatory and ethical considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
 Consensus ethical principles derived from internat ional guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
 Applicable ICH Good Clinical Practice (GCP) Guidelines
 Applica ble laws and regulations
The protocol , protocol  amendments, ICF, Invest igator Brochure, and other relevant docum ents 
(e.g. advertisements) must be submi tted to an IRB/IEC by [CONTACT_133419]/IEC before the study  is initiated.
Any amendments to the protocol will require IRB/IEC approval before implementation of changes 
made to the study  design, except for changes necessary  to eliminate an immediate hazard to study 
subjects.
The invest igator will be responsible for the following:
 Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually or more 
frequently in accordance wit h the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC
 Notifying the IRB/IEC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
 Provi ding oversight of the conduct of the study at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 536/2014 for clinical 
studi es (if applicable), and all other applicable local regulat ions
The study  will be perf ormed in accordance wi th the [COMPANY_008] policy  on Bioethics and Human 
Biological Samples.
A [ADDRESS_536782] igators and sub-investigators will provi de the sponsor with sufficient, accurat e financia l 
inform ation as requested to allow the sponsor to submit complete and accurate financia l 
certification or disclosure statem ents to the appropri ate regulatory  authori ties. Investi gators are 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 70of 95responsible for provi ding information on financial interests during the course of the study  and for 
1 year after complet ion of the study .
A 3 Informed consent process
The Investi gator or his/her representative will explain the nature of the study  to the subject or 
his/her legally  authori sed representative and answer all quest ions regarding the study .
Subjects must be informed that their participat ion is voluntary. Subjects or their legally authorised 
representative will be required to sign a statement of informed consent that meets the requirements 
of [ADDRESS_536783] (HIPAA) requirements, where applicable, and the IRB/IEC or study  centre.
The medical record must include a statem ent that written informed consent was obtained before 
the subject was enro lled in the study and the date the written consent was obtained. The authorised 
person obtaining the informed consent must also sign the ICF.
Subjects must be re -consented to the most current versi on of the ICF(s) during thei r parti cipat ion 
in the study .
A copy  of the ICF(s) must be provided to the subject or the subject’s legally authorised 
representative.
A subject who is rescreened is required to sign another ICF.
A [ADDRESS_536784] records or data sets 
transferred to the sponsor will contain only the ident ifier; subject names or any informat ion which 
woul d make the subject ident ifiable will not be transferred.
The subject m ust be informed that his/ her personal study -related data will be used by  [CONTACT_135711]. The level of disclo sure m ust al so be explained to the 
subject.
The subject must be informed that his/her medical records may be examined by [CONTACT_17080] y 
Assurance auditors or other authorised personnel appointed by [CONTACT_456], by [CONTACT_338433]/IEC members, and by [CONTACT_32857].
A [ADDRESS_536785] ical analysis plan, 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 71of 95interpretati on of the final data and reporting (presentations at internat ional congresses and 
publicat ions in peer reviewed journals) of the study.
The Execut ive Committee will make recommendations to [COMPANY_008] with regards to early 
stoppi[INVESTIGATOR_424599]. The
Execut ive Committee will be comprised of designated international academic leaders and 
nonvoting members o f the Sponsor, and will operate under an Executive Co mmittee charter.
National Lead Investigator (NLI) Committee
The National  Lead Invest igator (NLI) Committee will be comprised of NLIs from each country 
where the study  is conducted and supervised by [CONTACT_19305]. Members of the 
committee will be responsible for provi ding clinical guidance on study  implementation, 
recrui tment and study  conduct in their respect ive country .
Data Monitoring Committee (DMC)
An independent DMC will be appo inted and will report to th e Executive Commit tee. The DMC 
will be responsible for safeguarding the interests of the pat ients in the outcome study by [CONTACT_424647] , and f or revi ewing the overall conduct of the study . 
The DMC will have access to the individual treatment codes and be able to merge these with the 
collected study  data while the study  is ongoing. A DMC charter will be prepared to detail precise 
roles and responsibilit ies and procedures to ensure maintenance of th e blinding and integrit y of the 
study  in the review of accumulat ing data and interactions with the Execut ive Co mmit tee.
Clinical Event Adjudication (CEA) Committee
The role of the CEA committee is to independent ly review, interpret and adjudicate potential 
endpo ints that are experienced by [CONTACT_13935]. Endpo ints will be ident ified preliminary by [CONTACT_4520], and also by [CONTACT_424648]. The 
CEA committee members will not have access to indiv idual  treatm ent codes for any patient or 
clinical efficacy  endpoint and safet y event. The precise responsibilit ies and procedures applicable 
for CEA will be detailed in the CEA charter.
A 6 Dissemination of clinical study data
A descript ion of this clinical trial will be available on http://astrazenecaclinicaltrials.co m and 
http://www.clinicaltrials.gov as will the summary  of the main study result s when they are available. 
The clinical trial and/or summary of main study  results may also be available on other websites 
according to the regulat ions of the countries in which the main study  is conducted.
A [ADDRESS_536786] data relating to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designe e electroni cally  (e.g. laboratory  data). The Investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_424649].
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 72of 95The Investigator must maintain accurate documentation (source data) that sup ports the information 
entered in the CRF.
The Invest igator must permit study -related monitoring, audits, IRB/IEC review, and regul atory 
agency  inspect ions and provide direct access to source data documents.
The sponsor or designee is responsible for the data management of this study  including qualit y 
checking o f the data.
Study  monitors will perform  ongoing source data verification to confirm that data entered into the 
CRF by [CONTACT_31855], complete, and verifiable from source docum ents; 
that the saf ety and rights of  subjects are being protected; and that the study  is being conducted in 
accordance with the currently approved protocol  and any other study agreements, ICH GCP, and 
all applicable regulatory  requi rements.
Records and docum ents, including signed ICFs, pertaining to the conduct of this study  must be 
retained by [CONTACT_325411] [ADDRESS_536787] igator’s site.
Data reported on the CRF that are transcribed from source documents must be consistent with the source 
documents or the discre pancies must be explained. The Investigator may need to request previous medical 
records or transfer records, depending on the study. Also, current medical records must be available.
A [ADDRESS_536788] igator 
will be designated by  [CONTACT_424650].
Authorship will be determined by [CONTACT_424651].
Appendix B Adverse event definitions and additional safety information
B 1 Definition of adverse events
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 73of 95An adverse event is the development of any untoward medical occurrence in a subject or clinica l 
study  subject administered a medicinal product and which does not necessarily have a causa l 
relationship with this treatm ent. An AE can therefore be any unfavourable and unintended sign 
(e.g. an abnorm al laboratory  finding), symptom (for example nausea, chest pain), or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.
The term  AE is used to include both seri ous and non-serious AEs and can include a deteri oration 
of a pre -existing medical occurrence. An AE may occur at any  time, including run- in or washout 
periods, even if no Study  treatm ent has been administered.
B 2 Definitions of serious adverse event
A serious adverse event is an AE occurring during any study  phase (i .e., run -in, treatment, 
washout, follow -up), that fulfils one or more of the fo llowing cri teria:
 Results in death
 Is immediately life -threatening
 Requi res in -subject hospi [INVESTIGATOR_103421]
 Results in persistent or significant disabilit y or incapaci ty
 Is a congenital abnormalit y or birth defect
 Is an important medical event that may jeopardise the subject or may  require medical  
treatm ent to prevent one of the outcomes listed above.
B 3 Life threatening
‘Life -threatening’ means that the subject was at immediate risk o f death fro m the AE as it occurred 
or it is suspected that use or continued use o f the product would result in the subject’s death. ‘Life -
threatening’ does not mean that had an AE occurred in a more severe form it might have caused 
death (e.g., hepatit is that resolved wit hout hepatic failure).
B 4 Hospi[INVESTIGATOR_424600] a serious AE, although the reasons for 
it may be (e.g., bronchospasm, laryngeal oedema). Hospi[INVESTIGATOR_2144]/or surgical operations 
planned before or during a study are not con sidered AEs if the illness or disease existed before the 
subject was enro lled in the study , provi ded that i t did not deteri orate in an unexpected way  during 
the study .
B 5 Important medical event or medical treatment
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 74of 95Medical and scient ific judgement shoul d be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or resul t in 
death, hospi [INVESTIGATOR_72913], disabili ty or incapacit y but may jeopardi ze the subject or may requi re 
medical treatment to prevent one or more outcomes listed in the definit ion of serious. These should 
usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgement must be used.
 Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
 Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment 
with N-acetylcysteine
 Intensive treatment in an emergency room or at home for a llergic bronchospasm
 Blood dy scrasias (e.g. neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_72913]
 Development of drug dependency or drug abuse
B 6 Intensity rating scale:
1. mild (awareness of sign or symptom , but easily  tolerated)
2. moderate (di scomf ort sufficient to cause interference with normal act ivities)
3. severe (incapacitat ing, with inabilit y to perform norm al activities)
It is important to distinguish between serious and severe AEs. Severit y is a measure of intensit y 
whereas seriousness is defined by [CONTACT_73010] B 2. An AE of severe intensit y need not 
necessarily be considered serious. For example, nausea that persists for several hours may be 
considered severe nausea, but not a SAE unless it meets the criteria shown in Appendix B 2. On 
the other hand, a stroke that results in only a limited degree of disabilit y may be considered a mild 
stroke but would be a SAE when it satisfies the criteria shown in Appendix B 2.
B 7 A Guide to Interpreting the Causality Question
When assessing causali ty consider the following factors when deciding if there is a ‘reasonable 
possibilit y’ that an AE m ay have been caused by  [CONTACT_33641].
 Time Course. Exposure to suspect drug. Has the subject actually received the suspect 
drug? Did the AE occur in a reasonable temporal  relationship to th e administration of 
the suspect drug?
 Consistency with known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmacology  and toxicology) or drugs of the same 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 75of 95pharmaco logical class? Or could the AE be anticipated from its pharmaco logical 
properties?
 De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_72918]?
 No al ternative cause. The AE cannot be reasonably explained by [CONTACT_309581], other drugs, other host or environmental factors.
 Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? [COMPANY_008] woul d not norm ally recommend or support a 
re-challenge.
 Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship.
In difficult cases, other factors could be considered such as:
 Is this a recognized feature of overdose of the drug?
 Is there a known mechanism?
Causalit y of ‘related’ is made if following a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’ of a causal relat ionship for the individual case. The expressio n ‘reasonable 
possibilit y’ of a causal relati onship is meant to convey, in general , that there are facts (evidence) 
or argum ents to suggest a causal relat ionship.
The causalit y assessment is performed based on the available data including enough inform ation 
to make an informed judgment. With limited or insufficient informat ion in the case, it is likely that 
the event(s) will be assessed as ‘not related’.
Causal relationship in cases where the disease under study  has deteri orated due to lack of effect 
shoul d be classified as no reasonable possibilit y.
B [ADDRESS_536789] that either causes harm to the 
participant or has the potential to cause harm to the participant.
A medication error is not lack of efficacy o f the drug, but rather a human or process related failure 
while the drug is in control of the study  site staff or parti cipant.
Medicat ion error includes situat ions where an error:
 Occurred
 Was i dentified and intercepted before the participant received the drug
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 76of 95 Did not occur, but circumstances were recognized that could have led to an error 
Examples of events to be reported in clinical studies as medication errors:
 Drug name [CONTACT_33165] n
 Dispensing error e.g. medicat ion prepared incorrectly, even if it was not actually 
given to the participant
 Drug not administered as indicated, for example, wrong route or wrong site of 
administration
 Drug not taken as indicated e.g. tablet disso lved in water when it should be taken as 
a solid tablet
 Drug not stored as instructed e.g. kept in the fridge when it shoul d be at room  
temperature
 Wrong participant received the medicat ion (excluding IxRS errors)
 Wrong drug administered to participant (excluding IxRS errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
 Errors related to or resulting fro m IxRS -including those which lead to one of the 
above listed events that would otherwise have been a medication error
 Parti cipant acci dentally  missed drug dose(s) e.g.  forgot to take medication
 Accidental  overdose (wil l be captured as an overdose)
 Parti cipant f ailed to return unused medicat ion or empt y packaging
 Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an AZ product
Medicat ion errors are not regarded as AEs but AEs may occur as a consequence of the 
medicat ion error.
Appendix C Cardiovascular related events
C 1 Myocardial Infarctions (MI)
MIs are not endpoints in this study  but unstable angina and myocardi al infarct ion shoul d be 
recorded as SAEs if serious criteria are met and additional informat ion be collected in specific 
eCRF. The di agnoses of  unstable angina and MI shoul d adhere to the standardised definit ions for 
endpo ints (Hi cks et al  2018) described in Appendix C 2
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 77of 95C 2 Diagnosis of MI and Unstable Angina
Myocardial infarction (MI)
The diagnosis of an MI shoul d be made according to standard clinical pract ice but is expected to 
align wi th the criteria from Third Universal Definiti on of  MI, i .e. detecti on of  a rise and/or fall  of 
cardi ac biomarkers such as troponin and at least one of the following: typi[INVESTIGATOR_424601] s, 
ischaemic ECG findings, imaging evidence of myocardial injury , or detecti on of  an intracoronary 
thrombus by [CONTACT_424652]  (Thygesen et al 2012 ).
The di agnosis shoul d be made by, or in consul tation wi th, a cardi ologist. The findings supporting 
the diagnosis should be documented in the descriptio n of the SAE in the eCRF.
Unstable Angina (UA )
Unstable Angina (UA) is not an endpo int in this study but should be recorded as SAEs (and DAEs 
when appropriate). The diagnosis o f an UA should be made accordi ng to standard clinical pract ice 
but is expected to align with the fo llowing definit ion:
The diagnosis of unstable angina will require ischemic chest pain (or equivalent) at rest [ADDRESS_536790] 1 
of the fo llowing cri teria:
1. New or worseni ng ST or T wave changes in ≥2 anatomically contiguous leads on 
a resting ECG (in the absence of LVH and LBBB):
a)transi ent (<20 minutes) ST elevation at the J point ≥ 0.2 m V in men (> 0.25 m V in men < 40 
years o ld) or ≥ 0.15 mV in wo men in leads V2- V3 and/o r ≥ 0.1 mV in other leads, or
b)horizontal  or down -slopi[INVESTIGATOR_345482] ≥ 0.10 mV, or
c)T-wave inversio n ≥ 0.2 m V
2. Definite evidence of myocardi al ischemia on myocardial  scintigraphy (clear reversible 
perfusio n defect), stress echocardiography (reversible wall motion abnorm ality), or MRI 
(myocardial  perfusio n deficit under pharmaco logic stress) that is believed to be responsible for the 
myocardial  ischemic symptom s/signs.
3. Angiographic evidence of ≥ 70% l esion and/or thrombus in an epi[INVESTIGATOR_424602]/signs.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 78of 95C 3 Stroke
Stroke is not an endpoint in this study  but shoul d be recorded as SAEs if serious cri teria are met, 
with additional informat ion e.g. classificat ion of stroke type (ischaemic, haemorrhagic, or 
undetermined) collected in a specific eCRF.
The diagnosi s of stroke shoul d be made according to standard clinical  practi ce and align wi th the 
definit ion for stroke in the standardized definit ions for endpoints (Hicks et al 2018 ) described in 
Appendix C 4and be differentiated vs Transient Ischaemic Attack (TIA).
C 4 Definition of Stroke and Transient Ischemic Attack
The distinction between an Ischemic Stroke and a Transient Ischemic Attack is the presence of 
infarction. Persi stence of symptoms ≥24 hours or until death3is an acceptable indicator of acute 
infarction in the absence of imaging evidence of infarction.
Transient Ischemic Attack
Transient ischemic attack (TIA) is defined as a transient epi[INVESTIGATOR_424603], spi[INVESTIGATOR_1831], or retinal ischemia, without acute infarction.
Stroke
Stroke is defined as an acute epi[INVESTIGATOR_256815], spi[INVESTIGATOR_36232], or retinal vascular injury as a result of haemorrhage or infarction.
Classification:
A. Ischemic Stroke
Ischemic stroke is defined as an acute epi[INVESTIGATOR_196545], spi[INVESTIGATOR_1304], or retinal dy sfunction caused 
by [CONTACT_256904].
Haemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic 
stroke with haemorrhagic transformation and not a haemorrhagic stroke.
B. Haemorrhagic Stroke
Haemorrhagic stroke is defined as an acute epi[INVESTIGATOR_424604]-traumatic intraparenchymal, intraventricular, or subarachnoid haemorrhage. NOTE: 
Subdural hematomas are intracranial haemorrhagic events and not strokes.
C. Undetermined Stroke
Undetermined stroke is defined as an acute epi[INVESTIGATOR_424605], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of haemorrhage or infarction but with 
insufficient informa tion to allow categorization as either ischemic or haemorrhagic.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 79of 95References:
Hicks KA et al. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll 
Cardiol 2018;71:1021–34 https://doi.org/10.1016/j.jacc.2017.12.[ADDRESS_536791] 20, 2014
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MSV, George MG, 
Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee J-M, Moseley ME, 
Peterson ED, Turan TN, Valderrama AL, Vinters HV; on behalf of the American Heart Association 
Stroke Council, Council on Cardiovascular Surgery  and Anesthesia, Council on Cardiovascular 
Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epi[INVESTIGATOR_424606], Council on Peripheral Vascular Disease, and Council on Nutrition, Physical Activity 
and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare 
professionals from the American Heart Association/American Stroke Association. Stroke. 
2013;44:2064 -2089.
Appendix D Genetics
D 1 Use/analysis of DNA
Genet ic variat ion may impact a subject’s response to th erapy , suscept ibilit y to, and severit y and 
progression of disease. Variable response to therapy ma y be due to genetic determinants that impact 
drug absorption, distribut ion, metabo lism, and excretion; mechanism of act ion of the drug; disease 
aetiology; and/or molecular subtype o f the disease being treated. Therefore, where local regulat ions 
and IRB/IEC allow, a bl ood sam ple will be collected for DNA analysis fro m consent ing subjects.
[COMPANY_008] intends to collect and store DNA for geneti c research to explore how genet ic 
variat ions may affect clinical parameters, risk and prognosis of diseases, and the response to
medicat ions. Genet ic research may lead to better understanding of diseases, better diagnosis of 
diseases or other improvements in health care and to the di scovery  of new di agnost ics, treatm ents 
or medicat ions.
In addition, collect ion of DNA samples from popul ations with well described clinical 
characterist ics may lead to improvements in the design and interpretati on of clinical trials and, 
possibly , to geneti cally guided treatment strategies.
Genet ic research may consist of the analysis of the structure of the subject´s DNA, i.e. the entire 
geno me.
The resul ts of genet ic analyses may be reported i n the clinical  study  report (CSR) or in a separate 
study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
The samples will be retained while research on heart failure with preserved eject ion fraction 
continues but no longer than 15 y ears or other period as per local requirements.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 80of 95D [ADDRESS_536792] of the m ain study .
Inclusion criteria
 For inclusio n in this genet ic research, subjects must fulfil all of the inclusio n criteria 
described in the main body o f the Clinical Study Protocol andProvi de informed consent 
for the gene tic sampling and analyses.
Exclusion criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in the 
main study  or any  of the fo llowing:
 Previous allogeneic bone marrow transplant
 Non-leukocyte depleted whole blood transfusio n in [ADDRESS_536793] ion
Withdrawal of consent for genetic research:
Subjects may withdraw from this genet ic research at any time, independent of any decisi on 
concerning participat ion in other aspects of the main study . Voluntary  withdrawal will not 
prejudice further treatm ent. Procedures for withdrawal  are outlined in Secti on 7of the main 
Clinical Study  Protocol .
Collection of samples for genetic research
The blood sample for genetic research will be obtained fro m the subjects at Visit 2. Although DNA 
is stable, early sample co llection is preferred to avoid introducing bias through excluding subjects 
who may withdraw due to an adverse event (AE), such subjects woul d be important to include in 
any genetic analysis. If for any reason the sample is not drawn at Visit 2, it may be taken at any 
visit unt il the last study visit. Only  one sample shoul d be collected per subj ect for geneti cs during 
the study . Sam ples will be collected, labelled, stored, and shipped as detailed in the Laboratory 
Manual.
Coding and storage of DNA samples
The processes adopted for the coding and storage of sam ples for geneti c analysis are important to 
maintain subject confident iality. Samples will be stored for a maximum of [ADDRESS_536794] visit, after which they will be destroyed. DNA is a finite resource that is used up 
during analyses. Samples will be stored and used until no further analyses are possible or the 
maximum storage time has been reached.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 81of 95An addit ional second code will be assigned to the blo od sample eit her before or at the time o f DNA 
extracti on replacing the informat ion on the sample tube. Thereafter, the sample will be ident ifiable 
only by [CONTACT_33160], uni que number. This number is used to ident ify the sample and corresponding 
data at the [COMPANY_008] genet ics laboratories, or at the designated organisat ion. No personal details 
ident ifying the individual will be available to any person ([COMPANY_008] employee or designated 
organi sations working wi th the DNA).
The link between the subject enrolment/randomisation code and the second number will be 
maintained and stored in a secure environment, with restricted access at [COMPANY_008] or designated 
organi sations. The link will be used toident ify the relevant DNA samples for analysis, facilitate 
correl ation of genoty pic resul ts with clinical data, allow regul atory  audit, and permit tracing of 
samples for destruction in the case of withdrawal of consent.
Ethical and regulatory requirements
The principles for ethical and regulatory  requirements for the study, including this genet ics 
research component, are outlined in Appendix A.
Informed consent
The genet ic component of this study  is optional and the subject may participate in other 
components of the main study without participating in the genetic co mponent. To participate in the 
genet ic component of the study  the subject m ust sign and date both the consent form  for the main 
study  and the genetic c omponent of the study. Copi[INVESTIGATOR_424607] e subject and the original filed at the study  centre. The Principal Invest igator(s) is 
responsible for ensuring that consent is given freely and that the subject unders tands that they may 
freely  withdrawal  from the genet ic aspect of the study at any t ime.
Subject data protection
[COMPANY_008] will not provide individual genoty pe resul ts to subjects, any  insurance com pany , any 
employer, thei r family members, general physician unless required to do so by  [CONTACT_2371].
Extra precautions are taken to preserve confidentialit y and prevent genet ic data being linked to the 
ident ity of the subject. In except ional circumstances, however, certain individuals might see both 
the genet ic data and the personal identifiers of a subject. For example, in the case of a medical 
emergency, an [COMPANY_008] Physician or an investigator might know a subject’s ident ity and al so 
have access to his or her genet ic data. In addition, Regulatory authorit ies may require access to the 
relevant files, though the subject’s medical inform ation and the genet ic files woul d remain 
physically separate.
Data management
Any genoty pe data generated in this study  will be stored at a secure system at [COMPANY_008] and/or
designated organizat ions to analyse the samples.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 82of 95[COMPANY_008] and its designated organi sations may share summary  results (such as genet ic 
differences from groups of individuals with a  d isease) from this genet ic research with other 
researchers, such as hospi [INVESTIGATOR_600], academic organisat ions or health insurance companies. This can be 
done by  [CONTACT_310449], where they can be combined wit h the results of 
similar studi es to learn even more about health and disease. The researchers can only use this 
inform ation for healt h-related research purposes. Researchers may see summary resul ts but they 
will not be able to see individual subject data or any personal ident ifiers.
Some or all  of the clinical datasets from the main study  may be mer ged wi th the genet ic data in 
a suitable secure environment separate from the clinical database.
Statistical methods and determination of sample size
The number of subjects that will agree to participate in the genet ic research is unknown. It is 
therefore not possible to establish whether sufficient data will be collected to allow a formal
statist ical evaluat ion or whether only descript ive statist ics will be generated. A Statist ical 
Analysis Plan may be prepared where appropriate.
Appendix E Handling of H uman Biological Samples
E 1 Chain of custody of biological samples
A full chain o f custody  is maintained for all samples throughout their lifecycle.
The Investi gator at each centre keeps full traceabilit y of collected biological samples from the 
subjects while in storage at the centre until shipment or disposal (where appropriate).
The sample receiver keeps full traceabilit y of the samples while in storage and during use until 
used or disposed of or until further shipment and keeps documentation of recei pt of  arrival.
[COMPANY_008] will keep oversight of the ent ire life cycle through internal procedures, monitoring o f 
study  sites, auditing or process checks, and contractual  requirements of external laboratory 
provi ders
Samples retained for further use will be stored in the AZ- assigned bi obanks and will be registered 
by [CONTACT_424653].
If requi red, [COMPANY_008] will ensure that remaining biological  samples are returned to the site 
according to local regulat ions or at the end of the retention period, whichever is the sooner.
E [ADDRESS_536795] withdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed of/destroyed, and the acti on documented. If samples are already analysed, [COMPANY_008] 
is not obliged to destroy  the resul ts of this research.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 83of 95As collect ion of the bio logical sample(s) i s an integral  part of the study , then the subject i s 
withdrawn from  further study  parti cipat ion.
The Investigator:
 Ensures subjects’ wit hdrawal o f informed consent to the use of donated samples 
is notified immediately to [COMPANY_008]
 Ensures that bio logical samples from that subject, if stored at the study  site, are 
immediately  identified, disposed of /destroy ed, and the action documented
 Ensures the organizat ion(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroy ed, the 
action docum ented and the signed document returned to the study  site
 Ensures that the subject and [COMPANY_008] are informed about the sample 
disposal .
[COMPANY_008] ensures the organizat ions holding the sam ples is/are informed about the withdrawn 
consent immediately  and that sam ples are di sposed of/destroy edand the acti on docum ented and 
returned to the study  site.
E 3 International Airline Transportation Association (IATA) 6.[ADDRESS_536796] SAMPLES
International Airline Transportation Association (IATA) classifies b iohazardous agents into 3 
categories (http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.htm). For 
transport purposes the classification of infectious substances according to risk groups was removed 
from the Dangerous Goods Regulation s in the 46th edition (2005). Infectious substances are now 
classified either as Category  A, Category B or Exempt. There is no direct relationship between 
Risk Groups and Categories A and B.
Category A Infectious Substances are infect ious substances in a form that, when exposure to it
occurs, is capable of causing permanent disabilit y, life- threatening or fatal  disease in otherwi se 
healt hy humans or animals. Category  A pathogens are e.g., Ebola, Lassa fever virus:
 Are to be packed and shipped in accordanc e with IATA Instructi on 602.
Category B Infectious Substances are infect ious Substances that do not meet the criteria for
inclusio n in Category  A. Category  B pathogens are e.g., Hepatit is A, B, C, D, and E viruses, 
Hum an immunodeficiency virus ty pes 1 and 2. They  are assigned the following UN number and 
proper shippi[INVESTIGATOR_72919]:
 UN 3373 –Biological Substance, Category  B
 Are to be packed in accordance with UN3373 and IATA 650
Exempt -all other materials wit h minimal risk of containing pathogens
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 84of 95 Clinical t rial samples will fall into Category  B or exempt under IATA 
regul ations
 Clinical trial samples will routinely be packed and transported at ambient
 Temperature in IATA 650 compliant packaging 
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.ht m)
 Biological samples transported in dry ice require additional dangerous 
goods specification for the dry- ice content
 IATA co mpliant courier and packaging materials should be use d for packing and 
transportation and packing should be done by [CONTACT_73013], as 
applicable
 Samples routinely transported by  [CONTACT_424654] a safe and app ropri ate 
way to contain any  risk of  infect ion or contamination by [CONTACT_424655]/containment materials at all t imes. The IATA [ADDRESS_536797] or 
rail transport is used.
Appendix F Actions required in cases of increases in liver biochemistry and 
evaluation of Hy’s Law (not applicable)
Appendix G Medical device incidents: definition and procedures for recording, 
evaluating, follow -up, and reporting (not applicable)
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 85of 95Appendix H Abbreviations
Abbreviation or Explanation
special term
AE Adverse Event
BP Blood Pressure
CEA Clinical Event Adjudication
COPD Chronic Obstructive Pulmonary Disease
COVID -[ADDRESS_536798] (IRB) and
Independent Ethics Committee (IEC)
ECG Electrocardiogram
EDC Electronic Data Capture
EHRs Electronic Health Records
FAS Full Analysis Set
GCP Good Clinical Practice
HF Heart Failure
HFpEF Heart Failure with Preserved Ejection Fraction
HR Hazard Ratio
ICF Infor med Consent Form
ICH International Conference on Harmonisation
International If a study is conducted in several countries the International Co -ordinating
Co-ordinating Investigator is the Investigator co -ordinating the Investigators and/or
Investigator activities internationally.
IxRS Interactive Voice/Web Response System
KCCQ Kansas City Cardiomyopathy Questionnaire
LAE Left Atrial Enlargement
LSLV Last Subject Last Visit
LVEF Left Ventricular Ejection Fraction
MI Myocardial Infarction
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 86of 95NYHA [LOCATION_001] Heart Association
PACD Primary Analysis Censoring Date
PTDV Prem ature Treatment Discontinuation Visit
PI [INVESTIGATOR_424608]
T2D Type 2 Diabetes Mellitus
Appendix I   [LOCATION_001] Heart Association (NYHA) Functional Classification
Class Patient symptoms
I No limitat ion of physical act ivity.  Ordinary  physical  activity does
not cause undue fat igue, palpi[INVESTIGATOR_3116], dyspnoea (shortness of breath).
II Slight limitation o f physical act ivity. Comfortable at rest. Ordinary
physical act ivity results in fat igue, palpi[INVESTIGATOR_3116], dy spnea (shortness of
breath).
III Marked limitation o f physical act ivity. Comfortable at rest. Less
than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], or dyspnea.
IV Unable to carry  on any physical act ivity without discomfort.
Symptom s of heart failure at rest. If any  physical activi ty is
undertaken, discomfort increases.
Appendix J The KC Cardiomyopathy Questionnaire
The KC Cardiomyopathy Questionnaire
The following questions refer to your heart failure and how it may affect your life. Please read and 
complete the following questions. There are no right or wrong answers. Please mark the answer that 
best applies to you.
1.Heart failure affects different people in different ways. Some feel shortness of breath while
others feel fatigue. Please indicate how much you are limited by [CONTACT_119014] (shortness of 
breath or fatigue) in your ability to do the following activities over the past [ADDRESS_536799] an Xin one box on each line
Not atLimited for
Extremely Quite a bit Moderately  Slightly other reasonsActivity allLimited Limited Limited Limited or did not doLimitedthe activity
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 87of 95Dressing yourself❏ ❏ ❏ ❏ ❏ ❏
Showering/Bathing❏ ❏ ❏ ❏ ❏ ❏
Walking 1 block
❏ ❏ ❏ ❏ ❏ ❏ on level ground
Doing yardwork,
❏ ❏ ❏ ❏ ❏ ❏housework or
carrying groceries
Climbing a flight
❏ ❏ ❏ ❏ ❏ ❏of stairs without
stoppi[INVESTIGATOR_424609]
❏ ❏ ❏ ❏ ❏ ❏ jogging (as if to
catch a bus)
2.Compared with [ADDRESS_536800] your symptoms of heart failure (shortness of breath, 
fatigue, or ankle swelling) changed?
My symptoms of heart failure have become…
Much Slightly Not Slightly Much I’ve had no sym ptoms
worse worse changed better better over the last 2 weeks
❏ ❏ ❏ ❏ ❏ ❏
3.Over the past [ADDRESS_536801] swelling in your feet, ankles or legs when 
you woke up in the morning?
[ADDRESS_536802] 2 weeks
every day
❏ ❏ ❏ ❏ ❏
4.Over the past 2 weeks , how much has swelling in your feet, ankles or legs bothered you?
It has been ...
Extremely Quite a bit Moderately Slightly Not at all I’ve had no
bothersome bothersome bothersome bothersome bothersome swelling
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 88of 95❏ ❏ ❏ ❏ ❏ ❏
5.Over the past 2 weeks , on average, how many times has fatigue limited your ability to do what 
you want?
All of the Several At least [ADDRESS_536803] 2
❏day day every day
❏week weeks
❏ ❏ ❏ ❏ ❏
6.Over the past 2 weeks , how much has your fatigue bothered you?
It has been ...
Extremely Quite a bit Moderately Slightly Not at all I’ve had no
bothersome bothersome bothersome bothersome bothersome fatigue
❏ ❏ ❏ ❏ ❏ ❏
7.Over the past 2 weeks, on average, how many times has shortness of breath limited your 
ability to do what you wanted?
All 
of 
the
timeSeveral 
times 
per 
dayAt 
least 
once 
a 
day3 or 
more 
times 
per week 
but not 
everyday1 – [ADDRESS_536804] 2 
weeks
❏ ❏ ❏ ❏ ❏          ❏ ❏
8.Over the past 2 weeks , how much has your shortness of breath bothered you?
It has been ...
Extremely Quite a bit Moderately Slightly Not at all I’ve had no
bothersome bothersome bothersome bothersome bothersome shortness of breath
❏ ❏ ❏ ❏ ❏ ❏
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 89of 959.Over the past [ADDRESS_536805] 3 pi[INVESTIGATOR_384824] ?
Every [ADDRESS_536806] 2 weeks
❏ ❏ ❏ ❏ ❏
10.Heart failure symptoms can worsen for a number of reasons. How sure are you that you
know what to do, or whom to call, if your heart failure gets worse?
Not at Not very Somewhat Mostly Completely
all sure sure sure sure
❏sure
❏ ❏ ❏ ❏
11.How well do you understand what things you are able to do to keep your heart failure
symptoms from getting worse? (for example, weighing yourself, eating a low salt diet etc.)
Do not Do not understand Somewhat Mostly understand Completely
understand at all very well understand
❏understand
❏ ❏ ❏ ❏
12.Over the past 2 weeks , how much has your heart failure limited your enjo yment of life?
It has extremely It has limited myIt has 
moderately It has slightlyIt has not
limited mylimited my enjoyment of life limited my limited myenjoyment of 
lifeenjoyment of life quite a bit enjoyment of life enjoyment of lifeat all
❏ ❏ ❏ ❏ ❏
13.If you had to spend the rest of your life with your heart failure the way it is right now , how 
would you feel about this?
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 90of 95Not at all Mostly Somewhat Mostly Completely 
satisfiedsatisfied dissatisfied satisfied satisfied
❏ ❏ ❏ ❏ ❏
14.Over the past [ADDRESS_536807] you felt discouraged or down in the dumps because of 
your heart failure?
I felt that way all I felt that way most  I occasionally I rarely felt that I never felt that
of the time of the time felt that way way way
❏ ❏ ❏ ❏ ❏
15.How much does your heart failure affect your lifestyle? Please indicate how your heart 
failure may  have limited your participation in the following activities over the past [ADDRESS_536808] an Xin one box on each line
Does not
Severely Limited Moderately SlightlyDid not apply or
Activity limit at did not dolimited quite a bit limited limitedall for other
reasons
Hobbies,
Recreational                ❏ ❏ ❏ ❏ ❏ ❏
activities
Working or
doing
❏ ❏ ❏ ❏ ❏ ❏household
chores
Visiting
family
❏ ❏ ❏ ❏ ❏ ❏or friends out
of your home
Intimate
relationships
❏ ❏ ❏ ❏ ❏ ❏with loved
ones
Copyright © 1992 –2005 John Spertus, MD, MPH Original US English
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 91of [ADDRESS_536809] no problems walking 
I have slight problems walking 
I have moderate problems walking 
I have severe problems walking 
I am unable to walk 
SELF -CARE
I have no problems washing or dressing myself 
I have slight problems washing or dressing myself 
Ihave moderate problems washing or dressing myself 
I have severe problems washing or dressing myself 
I am unable to wash or dress myself 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 92of 95USUAL ACTIVITIES (e.g. work, study, housework,
family or leisure activities)
I have no problems doing my usual activities 
I have slight problems doing my usual activities 
I have moderate problems doing my usual activities 
I have severe problems doing my usual activities 
I am unable to do my usual activities 
PAIN / DISCOMFORT
I have no pain or discomfort 
I have slight pain or discomfort 
I have moderate pain or discomfort 
I have severe pain or discomfort 
I have extreme pain or discomfort 
ANXIETY / DEPRESSION
I am not anxious or depressed 
I am slightly anxious or depressed 
I am moderately anxious or depressed 
I am severely anxious or depressed 
I am extremely anxious or depressed 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 93of 95We would like to know how good or bad your health is
TODAY.
This scale is numbered from 0 to 100.
[ADDRESS_536810] health you can imagine.
Mark an X on the scale to indicate how your health is TODAY.
Now, please write the number you marked on the scale in the box below.
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 94of 95
[LOCATION_003] (English) © 2009 EuroQol Group. EQ -5D™ is a trade mark of the EuroQol Group
YOUR HEALTH TODAY = 
Clinical Study Protocol –Version 4.0, 12thNov 2020 [COMPANY_008]
D169CC00001 –Dapa HFpEF
CONFIDENTIAL AND PROPRIETARY 95of 95
Appendix L Patient Global Impression of Severity for Heart Failure 
Symptoms
Patient Global Impression of Severity for Heart Failure Symptoms
Overall, how would you rate the severity of your heart failure symptoms today?
No sy mptoms
Very  mild
Mild
Moderate
Severe
Very  Severe
SIGNATURE [CONTACT_73032] a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d169cc00001-csp-v4
Document Title: D169CC00001 Clinical Study Protocol version 4
Document ID: Doc ID-003827083
Version Label: 6.[ADDRESS_536811] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
13-Nov-2020 13:23 UTC Content Approval
16-Nov-2020 16:15 UTC Content Approval
13-Nov-2020 07:36 UTC Content Approval
16-Nov-2020 08:56 UTC Content Approval
13-Nov-2020 08:29 UTC Qualified Person Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]